menu
    • menu
    [{"orgOrder":0,"company":"Healis Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2022","type":"Acquisition","leadProduct":"Botulinum Toxin A","moa":"\nSNAP25","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Healis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Healis Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Healis Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Charite University, Berlin, Germany","sponsor":"Bionorica SE","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BX-1","moa":"11-beta-HSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Charite University, Berlin, Germany","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Charite University, Berlin, Germany \/ Bionorica SE","highestDevelopmentStatusID":"8","companyTruncated":"Charite University, Berlin, Germany \/ Bionorica SE"},{"orgOrder":0,"company":"Minerva Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"MIN-117","moa":"5-HT 1A receptor (HTR1A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Minerva Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Minerva Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Minerva Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Reviva Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"RP5063","moa":"5-HT 1A receptor (HTR1A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reviva Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reviva Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reviva Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"HaEmek Medical Center, Israel","sponsor":"MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HaEmek Medical Center, Israel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HaEmek Medical Center, Israel \/ MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA","highestDevelopmentStatusID":"8","companyTruncated":"HaEmek Medical Center, Israel \/ MAPS Public Benefit Corporation (MAPS PBC) 3141 Stevens Creek Blvd, #40547 San Jose, CA 95117 USA"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocin","moa":"5-HT 2A receptor (HTR2A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"||5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tianeptine Oxalate","moa":"5-HT reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"EmpathBio","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"EMP-01","moa":"5-HT\/noradrenaline","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ATAI Life Sciences \/ EmpathBio","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ EmpathBio"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor||5-hydroxytryptamine receptor 6; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Cantor Fitzgerald","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Cantor Fitzgerald","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Cantor Fitzgerald"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2021","type":"Series B Financing","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ RA Capital Management"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT1A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"F17464","moa":"5-HT1A receptor\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Licensing Agreement","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Catalent Pharma Solutions \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Mind Medicine"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"MM-120","moa":"5-HT1A\/2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cariprazine Hydrochloride","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"BPL-003","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Acquisition","leadProduct":"Bretisilocin","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":1.2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Abbvie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Abbvie Inc"},{"orgOrder":0,"company":"Cybin","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CYB004","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Deuterated Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Fluence","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Deuterated Tryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Fluence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fluence \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Fluence \/ Cybin"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Berenberg","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Public Offering","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Berenberg","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Berenberg"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Cybin","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Acquisition","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Cybin","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Cybin"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Small Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Small Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Small Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Small Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Dimethyltryptamine","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biomind Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"GH001","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"GH001","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"GH Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"GH001","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GH Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"GH Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GH Research \/ Undisclosed"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Series A Financing","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Seleni Institute","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Seleni Institute","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Seleni Institute"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"MPM BioImpact","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ MPM BioImpact","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ MPM BioImpact"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Isoprocin Prodrug","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Lysergide D-tartrate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Financing","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Undisclosed"},{"orgOrder":0,"company":"Beckley Psytech","sponsor":"Ksana Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Mebufotenin Benzoate","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beckley Psytech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beckley Psytech \/ Ksana Health","highestDevelopmentStatusID":"8","companyTruncated":"Beckley Psytech \/ Ksana Health"},{"orgOrder":0,"company":"Filament Health","sponsor":"University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"PEX010","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Filament Health \/ University of British Columbia","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ University of British Columbia"},{"orgOrder":0,"company":"Filament Health","sponsor":"University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"PEX010","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Filament Health \/ University of British Columbia","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ University of British Columbia"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"RE104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RE104","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"TRYP-0082","moa":"5-HT2A receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Impel Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INP105","moa":"5-HT2A\/D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Impel Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Impel Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Impel Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seton Healthcare Family","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Botulinum toxin type A","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seton Healthcare Family","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Seton Healthcare Family \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seton Healthcare Family \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"Allergan","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Onabotulinumtoxin A","moa":"ACh release","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Allergan","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan \/ Undisclosed"},{"orgOrder":0,"company":"BioXcel Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BXCL501","moa":"ADRA2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioXcel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"BioXcel Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"BioXcel Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"Arbor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"AR08","moa":"Adrenergic receptor (ADR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arbor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arbor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arbor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Ontario Lung Association","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Ontario Lung Association","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Ontario Lung Association"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"National Institute on Alcohol Abuse and Alcoholism | VA Puget Sound Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ National Institute on Alcohol Abuse and Alcoholism | VA Puget Sound Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ National Institute on Alcohol Abuse and Alcoholism | VA Puget Sound Health Care System"},{"orgOrder":0,"company":"Seattle Institute for Biomedical and Clinical Research","sponsor":"US Department of Defense | VA Puget Sound Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Prazosin Hydrochloride","moa":"Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seattle Institute for Biomedical and Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Seattle Institute for Biomedical and Clinical Research \/ US Department of Defense | VA Puget Sound Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"Seattle Institute for Biomedical and Clinical Research \/ US Department of Defense | VA Puget Sound Health Care System"},{"orgOrder":0,"company":"SHIRE PLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Guanfacine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SHIRE PLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SHIRE PLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SHIRE PLC \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Terran Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Idazoxan","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Terran Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Terran Biosciences"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"US WorldMeds","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"New York State Psychiatric Institute \/ US WorldMeds","highestDevelopmentStatusID":"8","companyTruncated":"New York State Psychiatric Institute \/ US WorldMeds"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | RTI International | Michael E. DeBakey VA Medical Center | US WorldMeds | Foundation for Advancing Veterans' Health Research"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMeds \/ Undisclosed"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMeds \/ Undisclosed"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Lofexidine","moa":"Adrenergic receptor alpha-2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US WorldMeds","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"US WorldMeds \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"US WorldMeds \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Columbia Northwest Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Carvedilol","moa":"Adrenergic receptor beta | Adrenergic receptor alpha-1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia Northwest Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Columbia Northwest Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Columbia Northwest Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"Foundation for a Smoke Free World","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rose Research Center \/ Foundation for a Smoke Free World","highestDevelopmentStatusID":"8","companyTruncated":"Rose Research Center \/ Foundation for a Smoke Free World"},{"orgOrder":0,"company":"NRx Pharmaceuticals","sponsor":"Massachusetts General Hospital | Target Health Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2016","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NRx Pharmaceuticals \/ Massachusetts General Hospital | Target Health Inc.","highestDevelopmentStatusID":"8","companyTruncated":"NRx Pharmaceuticals \/ Massachusetts General Hospital | Target Health Inc."},{"orgOrder":0,"company":"The Alfred","sponsor":"Blue Bell Health, Australia | Gold Coast Hospital and Health Service","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Amino Acid","year":"2022","type":"Inapplicable","leadProduct":"Cycloserine","moa":"Alanine racemase | D-alanylalanine synthetase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The Alfred","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"The Alfred \/ Blue Bell Health, Australia | Gold Coast Hospital and Health Service","highestDevelopmentStatusID":"8","companyTruncated":"The Alfred \/ Blue Bell Health, Australia | Gold Coast Hospital and Health Service"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"The Depressive and Bipolar Disorder Alternative Treatment Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Curcumin","moa":"Albendazole monooxygenase (CYP3A4)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ The Depressive and Bipolar Disorder Alternative Treatment Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ The Depressive and Bipolar Disorder Alternative Treatment Foundation"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NBI-1065846","moa":"AMPA receptor\/GPR139","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"E-therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ETS6103","moa":"analgesics (mixed opiate receptor agonists\/antagonists)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"E-therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"E-therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"E-therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"JNJ-42165279","moa":"Anandamide amidohydrolase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"JNJ-42165279","moa":"Anandamide amidohydrolase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"PF-04457845","moa":"Anandamide amidohydrolase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"SpringWorks Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"PF-04457845","moa":"Anandamide amidohydrolase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SpringWorks Therapeutics","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.40999999999999998,"dosageForm":"Tablet","sponsorNew":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"SpringWorks Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY2452473","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Emotional Brain NY","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Emotional Brain NY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emotional Brain NY \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emotional Brain NY \/ Undisclosed"},{"orgOrder":0,"company":"Emotional Brain NY","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2014","type":"Inapplicable","leadProduct":"Testosterone","moa":"Androgen Receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Emotional Brain NY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emotional Brain NY \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emotional Brain NY \/ Undisclosed"},{"orgOrder":0,"company":"Humanetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"7-keto Dehydroepiandrosterone","moa":"androgens; steroids (androgens","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Humanetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Humanetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Humanetics \/ Undisclosed"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pipamperone","moa":"antianxiety agents\/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANeuroTech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Undisclosed"},{"orgOrder":0,"company":"ANeuroTech","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pipamperone","moa":"||antianxiety agents\/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ANeuroTech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"ANeuroTech \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"ANeuroTech \/ Johnson & Johnson"},{"orgOrder":0,"company":"PharmaNeuroBoost","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pipamperone","moa":"antianxiety agents\/neuroleptics (4-fluoro-4-piperidinobutyrophenone derivatives)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmaNeuroBoost","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaNeuroBoost \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmaNeuroBoost \/ Undisclosed"},{"orgOrder":0,"company":"Ostergotland County Council","sponsor":"BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Probiotic","year":"2012","type":"Inapplicable","leadProduct":"Lactobacillus Reuteri","moa":"Bacteria microbiome","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ostergotland County Council","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ostergotland County Council \/ BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ostergotland County Council \/ BioGaia Pharma | Ekhaga Foundation, Sweden | Medical Research Council of Southeast Sweden | University Hospital, Linkoeping | The Swedish Research Council | Swedish Society of Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"Bacterial 70S ribosome","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Alpha Wave Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Alpha Wave Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Alpha Wave Ventures"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series A Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Cerebral Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Cerebral Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Cerebral Therapeutics"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Public Offering","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.14999999999999999,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Jefferies"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Lightswitch Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Series B Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Lightswitch Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Lightswitch Capital"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"InVivium Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Tablet","sponsorNew":"Alto Neuroscience \/ InVivium Capital","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ InVivium Capital"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Wellcome Trust","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"ALTO-100","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Wellcome Trust","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Wellcome Trust"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2025","type":"Inapplicable","leadProduct":"Lithium Salicylate Proline","moa":"BDNF","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Propranolol Hydrochloride","moa":"Beta-2 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Invion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Nadolol","moa":"Beta-2 adrenergic receptor | Beta-1 adrenergic receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Invion","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Invion \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Invion \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"TV-1380","moa":"Butyrylcholinesterase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"GW Research","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GW Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GW Research \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GW Research \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Bazelet Nehushtan LtD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bazelet Nehushtan LtD.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bazelet Nehushtan LtD. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bazelet Nehushtan LtD. \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Nebraska Medical Center","sponsor":"Ananda Scientific","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Nebraska Medical Center \/ Ananda Scientific","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska Medical Center \/ Ananda Scientific"},{"orgOrder":0,"company":"University of Nebraska","sponsor":"Ananda Scientific | University of Texas at Austin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Nebraska","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Nebraska \/ Ananda Scientific | University of Texas at Austin","highestDevelopmentStatusID":"8","companyTruncated":"University of Nebraska \/ Ananda Scientific | University of Texas at Austin"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Langone Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ NYU Langone Health","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Langone Health"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"University Of Nebraska Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ananda Scientific \/ University Of Nebraska Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ University Of Nebraska Medical Center"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ananda Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"UCLA Jonsson Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ UCLA Jonsson Comprehensive Cancer Center"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Ananda Scientific | National Center for Complementary and Integrative Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"NYU Langone Health \/ Ananda Scientific | National Center for Complementary and Integrative Health","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Ananda Scientific | National Center for Complementary and Integrative Health"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"NYU Grossman School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ NYU Grossman School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ NYU Grossman School of Medicine"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Ananda Scientific","sponsor":"Lyotropic Delivery Systems","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ananda Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Softgel Capsule","sponsorNew":"Ananda Scientific \/ Lyotropic Delivery Systems","highestDevelopmentStatusID":"8","companyTruncated":"Ananda Scientific \/ Lyotropic Delivery Systems"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Undisclosed"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Undisclosed"},{"orgOrder":0,"company":"EmpowerPharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"EmpowerPharm","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"EmpowerPharm \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"EmpowerPharm \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Brockman Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Brockman Foundation","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Brockman Foundation"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"University of Sydney | Lambert Initiative for Cannabinoid Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"South West Sydney Local Health District \/ University of Sydney | Lambert Initiative for Cannabinoid Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"South West Sydney Local Health District \/ University of Sydney | Lambert Initiative for Cannabinoid Therapeutics"},{"orgOrder":0,"company":"SciSparc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SciSparc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SciSparc \/ Undisclosed"},{"orgOrder":0,"company":"Tilray","sponsor":"University of British Columbia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tilray","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tilray \/ University of British Columbia","highestDevelopmentStatusID":"8","companyTruncated":"Tilray \/ University of British Columbia"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ National Institute on Drug Abuse | Columbia University | New York State Psychiatric Institute | ClinStar"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Undisclosed"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Undisclosed"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Aelis Farma","sponsor":"Indivior","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aelis Farma","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Capsule","sponsorNew":"Aelis Farma \/ Indivior","highestDevelopmentStatusID":"8","companyTruncated":"Aelis Farma \/ Indivior"},{"orgOrder":0,"company":"Indivior","sponsor":"Aelis Farma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"AEF0117","moa":"Cannabinoid receptor 1 (CB1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Indivior \/ Aelis Farma","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Aelis Farma"},{"orgOrder":0,"company":"TO Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cannabis","moa":"Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Neuronal acetylcholine receptor subunit alpha-7; Delta-type opioid receptor; Mu-type opioid receptor; Peroxisome proliferator-activated receptor gamma; Transient receptor potential cation channel subfamily V member 1; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Transient receptor potential cation channel subfamily A member 1; Transient receptor potential cation channel subfamily M member 8; Transient receptor potential cation channel subfamily V member 2; Transient receptor potential cation channel subfamily V member 3; Transient receptor potential cat","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"TO Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"TO Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"TO Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Brlev Agricultural Crops","sponsor":"Bio-Sciences Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Cannabis","moa":"Cannabinoid receptor 1; Cannabinoid receptor 2; G-protein coupled receptor 12; Glycine receptor subunit alpha-1; Glycine receptor (alpha-1\/beta); Glycine receptor subunit alpha-3; N-arachidonyl glycine receptor; G-protein coupled receptor 55; 5-hydroxytryptamine receptor 1A; 5-hydroxytryptamine receptor 2A; Neuronal acetylcholine receptor subunit alpha-7; Delta-type opioid receptor; Mu-type opioid receptor; Peroxisome proliferator-activated receptor gamma; Transient receptor potential cation channel subfamily V member 1; Voltage-dependent T-type calcium channel subunit alpha-1G; Voltage-dependent T-type calcium channel subunit alpha-1H; Voltage-dependent T-type calcium channel subunit alpha-1I; Transient receptor potential cation channel subfamily A member 1; Transient receptor potential cation channel subfamily M member 8; Transient receptor potential cation channel subfamily V member 2; Transient receptor potential cation channel subfamily V member 3; Transient receptor potential cat","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Brlev Agricultural Crops","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brlev Agricultural Crops \/ Bio-Sciences Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Brlev Agricultural Crops \/ Bio-Sciences Pharma"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nabiximols","moa":"cannabinol derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Centre for Addiction and Mental Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Canadian Institutes of Health Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nabiximols","moa":"cannabinol derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Centre for Addiction and Mental Health \/ Canadian Institutes of Health Research","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Canadian Institutes of Health Research"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"PH15","moa":"Chemocell receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Itruvone","moa":"Chemosensory receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Acquisition","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":8.6999999999999993,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":8.6999999999999993,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Cerevel Therapeutics","sponsor":"Piper Sandler","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cerevel Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.45000000000000001,"dosageForm":"Tablet","sponsorNew":"Cerevel Therapeutics \/ Piper Sandler","highestDevelopmentStatusID":"8","companyTruncated":"Cerevel Therapeutics \/ Piper Sandler"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Emraclidine","moa":"CHRM4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CB1\/CB2 receptor||CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Anebulo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Selonabant","moa":"CNR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anebulo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Anebulo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anebulo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2021","type":"Inapplicable","leadProduct":"TNX-1300","moa":"Cocaine (Coca)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"National Institute on Drug Abuse | Premier","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2023","type":"Inapplicable","leadProduct":"TNX-1300","moa":"Cocaine (Coca)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse | Premier","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse | Premier"},{"orgOrder":0,"company":"Actinogen","sponsor":"AXIOM Real Time Metrics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ AXIOM Real Time Metrics","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ AXIOM Real Time Metrics"},{"orgOrder":0,"company":"Actinogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Undisclosed"},{"orgOrder":0,"company":"Actinogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Undisclosed"},{"orgOrder":0,"company":"Actinogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Undisclosed"},{"orgOrder":0,"company":"Actinogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Xanamem","moa":"Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Actinogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Actinogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actinogen \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Naproxen","moa":"||Cyclooxygenase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2015","type":"Inapplicable","leadProduct":"Metyrapone","moa":"CYP11B1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"Metyrapone","moa":"||CYP11B1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2020","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2016","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Embera NeuroTherapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2018","type":"Inapplicable","leadProduct":"EMB-001","moa":"CYP450","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Embera NeuroTherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Embera NeuroTherapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SXC-2023","moa":"Cystine\/glutamate transporter (SLC7A11)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promentis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Celerion | Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SXC-2023","moa":"Cystine\/glutamate transporter (SLC7A11)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Celerion | Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Promentis Pharmaceuticals \/ Celerion | Baylor College of Medicine"},{"orgOrder":0,"company":"Promentis Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SXC-2023","moa":"Cystine\/glutamate transporter (SLC7A11)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Promentis Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Promentis Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Promentis Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"ASP4345","moa":"D1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"ASP4345","moa":"D1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ITI-1284","moa":"D1\/D2 dopamine\/5-HT2A serotonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Intra-Cellular Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ITI-1284","moa":"D1\/D2 dopamine\/5-HT2A serotonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Intra-Cellular Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Intra-Cellular Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Intra-Cellular Therapies \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"CVL-871","moa":"D1\/D5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CTC-501","moa":"D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chase Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chase Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Lb-102","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lb-102","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lb-102","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LB Pharmaceuticals \/ Washington University School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Washington University School of Medicine"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"Lb-102","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"LB Pharmaceuticals","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"N-Methyl Amisulpride","moa":"D2\/D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LB Pharmaceuticals","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.23000000000000001,"dosageForm":"Capsule","sponsorNew":"LB Pharmaceuticals \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"LB Pharmaceuticals \/ Leerink Partners"},{"orgOrder":0,"company":"National Institute of Allergy and Infectious Diseases","sponsor":"Cipla","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Pramipexole Dihydrochloride","moa":"D2-like dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute of Allergy and Infectious Diseases","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"National Institute of Allergy and Infectious Diseases \/ Cipla","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Allergy and Infectious Diseases \/ Cipla"},{"orgOrder":0,"company":"Chase Therapeutics","sponsor":"Chinalink Asia Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series B Financing","leadProduct":"Pramipexole Dihydrochloride","moa":"D2-like dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chase Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet, Immediate Release","sponsorNew":"Chase Therapeutics \/ Chinalink Asia Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Chase Therapeutics \/ Chinalink Asia Holdings"},{"orgOrder":0,"company":"Boryung Pharmaceutical Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Olanzapine","moa":"D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boryung Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boryung Pharmaceutical Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Bioprojet","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BP1.4979","moa":"D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bioprojet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioprojet \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bioprojet \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"DAAO||enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neurocrine Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Luvadaxistat","moa":"enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":2.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":2.02,"dosageForm":"Undisclosed","sponsorNew":"Takeda Pharmaceutical \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Luvadaxistat","moa":"enzyme inhibitors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"University of Cincinnati","sponsor":"University of Louisville | Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Asenapine Maleate","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Cincinnati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Cincinnati \/ University of Louisville | Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"University of Cincinnati \/ University of Louisville | Merck & Co"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"JNJ-37822681","moa":"Dopamine D2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Otsuka Holdings","highestDevelopmentStatusID":"8","companyTruncated":"University of Chicago \/ Otsuka Holdings"},{"orgOrder":0,"company":"Duke University","sponsor":"Otsuka Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Brexpiprazole","moa":"Dopamine D2 receptor | Serotonin 1a (5-HT1a) receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Duke University \/ Otsuka Holdings","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Otsuka Holdings"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Iloperidone","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"University of Colorado, Denver \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Aripiprazole","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Quetiapine Hemifumarate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Intra-Cellular Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"ITI-007","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Intra-Cellular Therapies","highestDevelopmentStatusID":"8","companyTruncated":"New York State Psychiatric Institute \/ Intra-Cellular Therapies"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Intra-Cellular Therapies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Lumateperone Tosylate","moa":"Dopamine D2 receptor | Serotonin 2a (5-HT2a) receptor | Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Intra-Cellular Therapies","highestDevelopmentStatusID":"8","companyTruncated":"University of Chicago \/ Intra-Cellular Therapies"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Levodopa","moa":"Dopamine D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Providence Health & Services","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Levodopa","moa":"Dopamine D3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Providence Health & Services","highestDevelopmentStatusID":"8","companyTruncated":"University of British Columbia \/ Providence Health & Services"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Institute on Drug Abuse | McLean Hospital | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"GSK598809","moa":"Dopamine D3 receptor (D3R)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ National Institute on Drug Abuse | McLean Hospital | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ National Institute on Drug Abuse | McLean Hospital | GSK"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"NW-3509a","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"NW-3509a","moa":"Dopamine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Noven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Amphetamine Sulfate","moa":"Dopamine transporter | Synaptic vesicular amine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Noven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Noven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Noven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"G\u00f6teborg University","sponsor":"Arvid Carlsson Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OSU6162","moa":"Dopamine\/serotonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"G\u00f6teborg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"G\u00f6teborg University \/ Arvid Carlsson Research","highestDevelopmentStatusID":"8","companyTruncated":"G\u00f6teborg University \/ Arvid Carlsson Research"},{"orgOrder":0,"company":"G\u00f6teborg University","sponsor":"Arvid Carlsson Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"OSU6162","moa":"Dopamine\/serotonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"G\u00f6teborg University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"G\u00f6teborg University \/ Arvid Carlsson Research","highestDevelopmentStatusID":"8","companyTruncated":"G\u00f6teborg University \/ Arvid Carlsson Research"},{"orgOrder":0,"company":"Zhejiang Huahai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hypidone HCl","moa":"Dopamine\/serotonin receptors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Zhejiang Huahai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Huahai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Huahai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Huahai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Hypidone HCl","moa":"Dopamine\/serotonin receptors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Zhejiang Huahai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Huahai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Huahai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Zhejiang Huahai Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Hypidone HCl","moa":"Dopamine\/serotonin receptors","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Zhejiang Huahai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zhejiang Huahai Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zhejiang Huahai Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Sirtsei Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sirtsei Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sirtsei Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirtsei Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Sirtsei Pharmaceuticals, Inc.","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sirtsei Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sirtsei Pharmaceuticals, Inc. \/ Rho Inc","highestDevelopmentStatusID":"8","companyTruncated":"Sirtsei Pharmaceuticals, Inc. \/ Rho Inc"},{"orgOrder":0,"company":"Sirtsei Pharmaceuticals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sirtsei Pharmaceuticals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sirtsei Pharmaceuticals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sirtsei Pharmaceuticals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Undisclosed"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Undisclosed"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Orlando Health Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series B Financing","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Orlando Health Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Orlando Health Ventures"},{"orgOrder":0,"company":"Firefly Neuroscience","sponsor":"Arrivo BioVentures","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Firefly Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Firefly Neuroscience \/ Arrivo BioVentures","highestDevelopmentStatusID":"8","companyTruncated":"Firefly Neuroscience \/ Arrivo BioVentures"},{"orgOrder":0,"company":"Arrivo BioVentures","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SP-624","moa":"Epigenetic","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Arrivo BioVentures","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Arrivo BioVentures \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Arrivo BioVentures \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Basel","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Basel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Hospital Basel \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Basel \/ Mind Medicine"},{"orgOrder":0,"company":"Liechti Lab","sponsor":"Mind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Liechti Lab","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Liechti Lab \/ Mind Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Liechti Lab \/ Mind Medicine"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"University Hospital Basel","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ University Hospital Basel","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ University Hospital Basel"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Maastricht University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Agreement","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Maastricht University","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Maastricht University"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Liechti Lab","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Liechti Lab","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Liechti Lab"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Canaccord Genuity","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Financing","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Canaccord Genuity","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Canaccord Genuity"},{"orgOrder":0,"company":"Mind Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mind Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mind Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mind Medicine \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MindBio Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"LSD","moa":"ergot alkaloid derivatives","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MindBio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MindBio Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MindBio Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lars Vedel Kessing","sponsor":"Mental Health Services in the Capital Region, Denmark | Lundbeck Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lars Vedel Kessing","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Lars Vedel Kessing \/ Mental Health Services in the Capital Region, Denmark | Lundbeck Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Lars Vedel Kessing \/ Mental Health Services in the Capital Region, Denmark | Lundbeck Foundation"},{"orgOrder":0,"company":"Indiana University","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"LY500307","moa":"Estrogen receptor beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Indiana University \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Eli Lilly"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"BMS-986368","moa":"FAAH\/MGLL","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JZP150","moa":"FAAH2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"JZP150","moa":"FAAH2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2024","type":"Series B Financing","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.17999999999999999,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ F-Prime Capital","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ F-Prime Capital"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2023","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Glyph Allopregnanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaport Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPT-300","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seaport Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Basmisanil","moa":"GABA(A) receptor alpha-5 (GABRA5)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Brexanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | Congressionally Directed Medical Research Programs | VA Connecticut Healthcare System | Sage Therapeutics | RTI International | Yale University"},{"orgOrder":0,"company":"Brii Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BRII-296","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Brii Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Brii Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Brii Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Blackstone Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Blackstone Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Blackstone Life Sciences"},{"orgOrder":0,"company":"Praxis Precision Medicines","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"PRAX-114","moa":"GABAA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Praxis Precision Medicines","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Praxis Precision Medicines \/ Cowen","highestDevelopmentStatusID":"8","companyTruncated":"Praxis Precision Medicines \/ Cowen"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Allopregnanolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PureTech Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PureTech Health \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Darigabat","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Darigabat","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"INTRuST Consortium | U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Marinus Pharmaceuticals \/ INTRuST Consortium | U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"8","companyTruncated":"Marinus Pharmaceuticals \/ INTRuST Consortium | U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Marinus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ganaxolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Marinus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Marinus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Marinus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Zuranolone","moa":"GABA-A receptor; anion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ASP8062","moa":"GABAB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"ASP8062","moa":"GABAB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABAB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"ASP8062","moa":"GABAB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Astellas Pharma \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"Astellas Pharma \/ National Institutes of Health"},{"orgOrder":0,"company":"National Institute on Alcohol Abuse and Alcoholism","sponsor":"Astellas Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ASP8062","moa":"GABAB receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Alcohol Abuse and Alcoholism","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Alcohol Abuse and Alcoholism \/ Astellas Pharma","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Alcohol Abuse and Alcoholism \/ Astellas Pharma"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Arbaclofen Placarbil","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Canadian Tobacco Control Research Initiative","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Canadian Tobacco Control Research Initiative","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Canadian Tobacco Control Research Initiative"},{"orgOrder":0,"company":"Essentia Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Baclofen","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Essentia Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Essentia Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Essentia Health \/ Undisclosed"},{"orgOrder":0,"company":"LABORATORIO FARMACEUTICO C.T S.r.l","sponsor":"Latis","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"GET-73","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LABORATORIO FARMACEUTICO C.T S.r.l","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LABORATORIO FARMACEUTICO C.T S.r.l \/ Latis","highestDevelopmentStatusID":"8","companyTruncated":"LABORATORIO FARMACEUTICO C.T S.r.l \/ Latis"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Recognify Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Recognify Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recognify Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Recognify Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Recognify Life Sciences","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Acquisition","leadProduct":"RL-007","moa":"GABA-B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Recognify Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recognify Life Sciences \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Recognify Life Sciences \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP1R","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eli Lilly \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Eli Lilly \/ Undisclosed"},{"orgOrder":0,"company":"Lyric Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Ulimorelin","moa":"Ghrelin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lyric Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lyric Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lyric Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP1R","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Altimmune","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altimmune \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Undisclosed"},{"orgOrder":0,"company":"Psychiatric Centre Rigshospitalet","sponsor":"Neurobiology Research Unit","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psychiatric Centre Rigshospitalet","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Psychiatric Centre Rigshospitalet \/ Neurobiology Research Unit","highestDevelopmentStatusID":"8","companyTruncated":"Psychiatric Centre Rigshospitalet \/ Neurobiology Research Unit"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI1569912","moa":"GluN2B\/NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BI1569912","moa":"GluN2B\/NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BI1569912","moa":"GluN2B\/NMDA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"Allergan Aesthetics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Allergan Aesthetics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Allergan Aesthetics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allergan Aesthetics \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Allergan Aesthetics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"NYU Langone Health \/ Allergan Plc","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Allergan Plc"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gate Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"The University of Pittsburgh School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gate Neurosciences \/ The University of Pittsburgh School of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ The University of Pittsburgh School of Medicine"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Gate Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"4-Chlorokynurenine","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"VistaGen Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"National Center for Research and Development, Poland","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Celon Pharma \/ National Center for Research and Development, Poland","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ National Center for Research and Development, Poland"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"National Center for Research and Development, Poland","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder","sponsorNew":"Celon Pharma \/ National Center for Research and Development, Poland","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ National Center for Research and Development, Poland"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Esketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Celon Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Undisclosed"},{"orgOrder":0,"company":"VA Connecticut Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Connecticut Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VA Connecticut Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VA Connecticut Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"VA Connecticut Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Connecticut Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"VA Connecticut Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VA Connecticut Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"Zylorion Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Zylorion Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zylorion Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zylorion Health \/ Undisclosed"},{"orgOrder":0,"company":"TruDiagnostic","sponsor":"Wild Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"TruDiagnostic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"TruDiagnostic \/ Wild Health","highestDevelopmentStatusID":"8","companyTruncated":"TruDiagnostic \/ Wild Health"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2014","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"David Barbic","sponsor":"St Paul's Emergency Department Research Fund | Centre for Health Evaluation and Outcome Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2017","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"David Barbic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"David Barbic \/ St Paul's Emergency Department Research Fund | Centre for Health Evaluation and Outcome Sciences","highestDevelopmentStatusID":"8","companyTruncated":"David Barbic \/ St Paul's Emergency Department Research Fund | Centre for Health Evaluation and Outcome Sciences"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HMNC Brain Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Undisclosed"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Partnership","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Develco Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Develco Pharma","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Develco Pharma"},{"orgOrder":0,"company":"Ketabon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ketabon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ketabon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ketabon \/ Undisclosed"},{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Develco Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Develco Pharma \/ HMNC Brain Health","highestDevelopmentStatusID":"8","companyTruncated":"Develco Pharma \/ HMNC Brain Health"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Ontario Shores Centre for Mental Health Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"University Health Network, Toronto \/ Ontario Shores Centre for Mental Health Sciences","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Ontario Shores Centre for Mental Health Sciences"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"||Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Acadia Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Roth Capital Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Roth Capital Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Roth Capital Partners"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Titan Partners Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Titan Partners Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Titan Partners Group LLC"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Vyera Pharmaceuticals","sponsor":"Seelos Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vyera Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Vyera Pharmaceuticals \/ Seelos Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Vyera Pharmaceuticals \/ Seelos Therapeutics"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution for Inhalation","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"LongeVC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ LongeVC","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ LongeVC"},{"orgOrder":0,"company":"Freedom Biosciences","sponsor":"MBX Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Freedom Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Freedom Biosciences \/ MBX Capital","highestDevelopmentStatusID":"8","companyTruncated":"Freedom Biosciences \/ MBX Capital"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Private Placement","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Lind Partners"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Undisclosed"},{"orgOrder":0,"company":"Douglas CDMO","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NEW ZEALAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Douglas CDMO","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Douglas CDMO \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Douglas CDMO \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Lanicemine","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Merz Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Forest Laboratories \/ Merz Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Merz Pharma"},{"orgOrder":0,"company":"Forest Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Memantine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Forest Laboratories","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Forest Laboratories \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Forest Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Sutter Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Dextromethorphan Hydrobromide","moa":"Glutamate [NMDA] receptor subunit epsilon 1 | Sigma opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sutter Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sutter Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sutter Health \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Rislenemdaz","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Avalo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Rislenemdaz","moa":"Glutamate NMDA receptor; GRIN1\/GRIN2B","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Avalo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Avalo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Avalo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Osavampator","moa":"Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"American Foundation for Suicide Prevention | National Center for PTSD | VA Connecticut Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Perampanel","moa":"Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Yale University \/ American Foundation for Suicide Prevention | National Center for PTSD | VA Connecticut Healthcare System","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ American Foundation for Suicide Prevention | National Center for PTSD | VA Connecticut Healthcare System"},{"orgOrder":0,"company":"Biogen","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TTYKUKSFWHEBLI-DLBZAZTESA-N","moa":"Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biogen \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biogen \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MIJ821","moa":"Glutamate receptor ionotropic NMDA 2B (NMDAR2B)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MIJ821","moa":"Glutamate receptor ionotropic NMDA 2B (NMDAR2B)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"MIJ821","moa":"Glutamate receptor ionotropic NMDA 2B (NMDAR2B)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MIJ821","moa":"Glutamate receptor ionotropic NMDA 2B (NMDAR2B)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Acquisition","leadProduct":"MIJ821","moa":"Glutamate receptor ionotropic NMDA 2B (NMDAR2B)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0.77000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.77000000000000002,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"University of Oxford","sponsor":"Stanley Medical Research Institute | Sound Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Oxford","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Oxford \/ Stanley Medical Research Institute | Sound Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Oxford \/ Stanley Medical Research Institute | Sound Pharmaceuticals"},{"orgOrder":0,"company":"Sound Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ebselen","moa":"Glutathione peroxidase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sound Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sound Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sound Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beth Israel Deaconess Medical Center","sponsor":"Center de Neurosciences Psychiatrique, Lausanne, Switzerland","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beth Israel Deaconess Medical Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Effervescent","sponsorNew":"Beth Israel Deaconess Medical Center \/ Center de Neurosciences Psychiatrique, Lausanne, Switzerland","highestDevelopmentStatusID":"8","companyTruncated":"Beth Israel Deaconess Medical Center \/ Center de Neurosciences Psychiatrique, Lausanne, Switzerland"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Bitopertin","moa":"Glycine transporter 1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"TAK-041","moa":"G-protein-coupled receptor PGR3 (GPR139)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neurocrine Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TAK-041","moa":"G-protein-coupled receptor PGR3 (GPR139)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neurocrine Biosciences \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-203","moa":"H3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-203","moa":"H3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Perrigo Company plc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Inositol","moa":"Beta-amyloid||HCAR3\/NIACR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ Perrigo Company plc","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Perrigo Company plc"},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov Therapeutics \/ ECSOR"},{"orgOrder":0,"company":"Kinnov Therapeutics","sponsor":"ECSOR","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Cyproheptadine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kinnov Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kinnov Therapeutics \/ ECSOR","highestDevelopmentStatusID":"8","companyTruncated":"Kinnov Therapeutics \/ ECSOR"},{"orgOrder":0,"company":"Duke University","sponsor":"Philip Morris USA, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Meclizine Hydrochloride","moa":"Histamine H1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Duke University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Duke University \/ Philip Morris USA, Inc","highestDevelopmentStatusID":"8","companyTruncated":"Duke University \/ Philip Morris USA, Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ABT-288","moa":"Histamine H3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Scripps Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"JNJ-31001074","moa":"Histamine H3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Scripps Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Scripps Research Institute"},{"orgOrder":0,"company":"Indiana University","sponsor":"Stanley Medical Research Institute | Sheppard Pratt Health System | University of Maryland | Centers for Behavioral Health, LLC | Laureate Institute for Brain Research | University of Kansas Medical Center | University of California, Los Angeles | Yale Un","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Valacyclovir Hydrochloride","moa":"Human herpesvirus 1 DNA polymerase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indiana University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Indiana University \/ Stanley Medical Research Institute | Sheppard Pratt Health System | University of Maryland | Centers for Behavioral Health, LLC | Laureate Institute for Brain Research | University of Kansas Medical Center | University of California, Los Angeles | Yale Un","highestDevelopmentStatusID":"8","companyTruncated":"Indiana University \/ Stanley Medical Research Institute | Sheppard Pratt Health System | University of Maryland | Centers for Behavioral Health, LLC | Laureate Institute for Brain Research | University of Kansas Medical Center | University of California, Los Angeles | Yale Un"},{"orgOrder":0,"company":"Bionorica SE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"Bronchipret","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bionorica SE","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bionorica SE \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bionorica SE \/ Undisclosed"},{"orgOrder":0,"company":"POM Wonderful","sponsor":"Target Health Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2010","type":"Inapplicable","leadProduct":"Ellagic acid","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"POM Wonderful","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"POM Wonderful \/ Target Health Inc.","highestDevelopmentStatusID":"8","companyTruncated":"POM Wonderful \/ Target Health Inc."},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Dalhousie University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Dalhousie University","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Dalhousie University"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ KGK Science"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"Laboratoire Cosderma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Probiotic","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ Laboratoire Cosderma","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ Laboratoire Cosderma"},{"orgOrder":0,"company":"GTO Pharmaceutical, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sinecatechins","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GTO Pharmaceutical, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"GTO Pharmaceutical, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GTO Pharmaceutical, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Coronado Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Microorganism","year":"2014","type":"Inapplicable","leadProduct":"Trichuris Suis Ova","moa":"Immune","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Coronado Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Coronado Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Coronado Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Carbohydrate","year":"2014","type":"Inapplicable","leadProduct":"Lactose","moa":"Influenza Neuraminidase (Influ NA)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"University of Toronto","sponsor":"Lotte & John Hecht Memorial Foundation | Centre for Addiction and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Carbohydrate","year":"2014","type":"Inapplicable","leadProduct":"Lactose","moa":"Influenza Neuraminidase (Influ NA)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Toronto \/ Lotte & John Hecht Memorial Foundation | Centre for Addiction and Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"University of Toronto \/ Lotte & John Hecht Memorial Foundation | Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Columbia Northwest Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2010","type":"Inapplicable","leadProduct":"Lithium Carbonate","moa":"Inositol-1(or 4)-monophosphatase 1 | Glycogen synthase kinase-3","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia Northwest Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Columbia Northwest Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Columbia Northwest Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"VA Connecticut Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Connecticut Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Connecticut Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"VA Connecticut Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Iltoo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"ILT101","moa":"Interleukin-2 receptor subunit beta; Interleukin-2 receptor subunit alpha; Cytokine receptor common subunit gamma","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Iltoo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Iltoo Pharma"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Sirukumab","moa":"Interleukin-6","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Heckel Medizintechnik","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Massachusetts General Hospital \/ Heckel Medizintechnik","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Heckel Medizintechnik"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CX717","moa":"Ionotropic glutamate receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"RespireRx Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"RespireRx Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"BTRX-140","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlackThorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"CERC-501","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Neumora therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlackThorn Therapeutics \/ Neumora therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Neumora therapeutics"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Navacaprant","moa":"Kappa opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"University of British Columbia","sponsor":"Vancouver Coastal Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of British Columbia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of British Columbia \/ Vancouver Coastal Health","highestDevelopmentStatusID":"8","companyTruncated":"University of British Columbia \/ Vancouver Coastal Health"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"US Department of Defense | RTI International","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | RTI International","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ US Department of Defense | RTI International"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"National Institutes of Health | Reckitt Benckiser | National Center for Research Resources","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ National Institutes of Health | Reckitt Benckiser | National Center for Research Resources","highestDevelopmentStatusID":"8","companyTruncated":"The University of Pittsburgh School of Medicine \/ National Institutes of Health | Reckitt Benckiser | National Center for Research Resources"},{"orgOrder":0,"company":"Evon Medics","sponsor":"National Institute on Drug Abuse | Howard University | Family and Medical Counseling Service | Maryland Treatment Center | Clinics of Dr. Edwin Chapman","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Buprenorphine","moa":"Kappa opioid receptor | Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Evon Medics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evon Medics \/ National Institute on Drug Abuse | Howard University | Family and Medical Counseling Service | Maryland Treatment Center | Clinics of Dr. Edwin Chapman","highestDevelopmentStatusID":"8","companyTruncated":"Evon Medics \/ National Institute on Drug Abuse | Howard University | Family and Medical Counseling Service | Maryland Treatment Center | Clinics of Dr. Edwin Chapman"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Biohaven Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BHV-7000","moa":"KV7 potassium ion channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Biohaven Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biohaven Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Biohaven Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Med4Cure","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Funding","leadProduct":"Iadademstat","moa":"LSD1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Med4Cure","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Med4Cure"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Nice & Green","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.050000000000000003,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Nice & Green","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Nice & Green"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Undisclosed"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Spanish Ministry Of Science and Innovation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Spanish Ministry Of Science and Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Spanish Ministry Of Science and Innovation"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Vall d\u2019Hebron Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Vall d\u2019Hebron Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Vall d\u2019Hebron Hospital"},{"orgOrder":0,"company":"Oryzon Genomics","sponsor":"Maxim","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SPAIN","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Oryzon Genomics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Oryzon Genomics \/ Maxim","highestDevelopmentStatusID":"8","companyTruncated":"Oryzon Genomics \/ Maxim"},{"orgOrder":0,"company":"Columbia University","sponsor":"Oryzon Genomics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Vafidemstat","moa":"Lysine-specific histone demethylase 1 (LSD)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Columbia University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Columbia University \/ Oryzon Genomics","highestDevelopmentStatusID":"8","companyTruncated":"Columbia University \/ Oryzon Genomics"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Organovo Holdings","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Series C Financing","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.23000000000000001,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Organovo Holdings","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Organovo Holdings"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MapLight Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"AF710B","moa":"M1\/SIGMAR1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CVL-231","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CVL-231","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CVL-231","moa":"M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NV-5138","moa":"Mammalian target of rapamycin complex 1 (mTORC1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NV-5138","moa":"Mammalian target of rapamycin complex 1 (mTORC1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Navitor Pharmaceuticals \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Navitor Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"NV-5138","moa":"Mammalian target of rapamycin complex 1 (mTORC1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Navitor Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Navitor Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Navitor Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"NFL-101","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"NFL-101","moa":"MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Diverchim","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Agreement","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Diverchim S.A.","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Diverchim S.A."},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"NFL Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Plant Extract\/Herbal","year":"2021","type":"Public Offering","leadProduct":"Nicotine","moa":"||MAO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NFL Biosciences","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"NFL Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NFL Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"American BriVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Undisclosed"},{"orgOrder":0,"company":"American BriVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2024","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.67000000000000004,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Xinnovation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Xinnovation Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Xinnovation Therapeutics"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.67000000000000004,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.67000000000000004,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"American BriVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Polygala Tenuifolia Extract","moa":"MAO-A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Undisclosed"},{"orgOrder":0,"company":"Transcend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Methylone","moa":"MAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Transcend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Transcend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transcend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transcend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Methylone","moa":"MAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Transcend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Transcend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transcend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transcend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Methylone","moa":"MAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Transcend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Transcend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transcend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transcend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Methylone","moa":"MAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Transcend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transcend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Transcend Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Methylone","moa":"MAT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Transcend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transcend Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transcend Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Urovant Sciences","sponsor":"Dasman Diabetes Institute | Ion Channel Innovations","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Hmaxi-K","moa":"Maxi-K channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Urovant Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Urovant Sciences \/ Dasman Diabetes Institute | Ion Channel Innovations","highestDevelopmentStatusID":"8","companyTruncated":"Urovant Sciences \/ Dasman Diabetes Institute | Ion Channel Innovations"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"Melanocortin receptor 4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ALTO-300","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Melatonin","moa":"Melatonin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ADX71149","moa":"Metabotropic glutamate receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Mediti Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"MP-101","moa":"Metabotropic glutamate receptor 2 (mGluR2)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mediti Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Mediti Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Mediti Pharma \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"RO4995819","moa":"Metabotropic glutamate receptor 2 | Metabotropic glutamate receptor 3","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AZD2066","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Basimglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novartis Pharmaceuticals Corporation \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Stalicla","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Undisclosed"},{"orgOrder":0,"company":"Stalicla","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Agreement","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Stalicla","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stalicla","amount2":0.27000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.27000000000000002,"dosageForm":"Tablet","sponsorNew":"Stalicla \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Stalicla \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Mavoglurant","moa":"Metabotropic glutamate receptor 5","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"InterveXion Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IXT-m200","moa":"Methamphetamine (Meth)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"InterveXion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InterveXion Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"InterveXion Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"InterveXion Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"IXT-m200","moa":"Methamphetamine (Meth)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"InterveXion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InterveXion Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"InterveXion Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"InterveXion Therapeutics","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"IXT-m200","moa":"Methamphetamine (Meth)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"InterveXion Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InterveXion Therapeutics \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"InterveXion Therapeutics \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tempero Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tempero Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ Undisclosed"},{"orgOrder":0,"company":"Tempero Bio","sponsor":"8VC","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series B Financing","leadProduct":"TMP-301","moa":"mGlu5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tempero Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Capsule","sponsorNew":"Tempero Bio \/ 8VC","highestDevelopmentStatusID":"8","companyTruncated":"Tempero Bio \/ 8VC"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"Amygdala Neurosciences | National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Ans-6637","moa":"Mitochondrial aldehyde dehydrogenase (ALDH2)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ Amygdala Neurosciences | National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ Amygdala Neurosciences | National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"CeNeRx BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CX157","moa":"Monoamine oxidase type A (MAO-A)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"CeNeRx BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CeNeRx BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CeNeRx BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centanafadine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Denovo Biopharma","sponsor":"Curia","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Liafensine","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Denovo Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Denovo Biopharma \/ Curia","highestDevelopmentStatusID":"8","companyTruncated":"Denovo Biopharma \/ Curia"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"NLS Pharmaceutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"NLS Pharmaceutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2021","type":"Licensing Agreement","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ NLS Pharmaceutics"},{"orgOrder":0,"company":"NLS Pharmaceutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Mazindol","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NLS Pharmaceutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Controlled Release","sponsorNew":"NLS Pharmaceutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NLS Pharmaceutics \/ Undisclosed"},{"orgOrder":0,"company":"Clear Scientific","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methamphetamine Hydrochloride","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clear Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clear Scientific \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Clear Scientific \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"University of Pennsylvania","sponsor":"Saniona | The Dana Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NS2359","moa":"Monoamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Pennsylvania","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Pennsylvania \/ Saniona | The Dana Foundation","highestDevelopmentStatusID":"8","companyTruncated":"University of Pennsylvania \/ Saniona | The Dana Foundation"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Partnership","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Private Placement","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.029999999999999999,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Alzamend Neuro","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Latozinemab","moa":"monoclonal antibodies: neural","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alzamend Neuro","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alzamend Neuro \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alzamend Neuro \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Navitor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPN-820","moa":"mTORC1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Supernus Pharmaceuticals \/ Navitor Pharmaceuticals"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"INDV-6001","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Temple University","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Naloxegol Oxalate","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Temple University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Temple University \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Temple University \/ AstraZeneca"},{"orgOrder":0,"company":"Alkermes Plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Samidorphan","moa":"Mu opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alkermes Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Alkermes Plc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alkermes Plc \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"National Drug Abuse Treatment CTN | The Emmes Company, LLC | Harvard Medical School (HMS and HSDM) | University of Pennsylvania | NYU Langone Health | Icahn School of Medicine at Mount Sinai | Alameda Health System | Weill Medical College of Cornell Unive","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CAS 52485-79-7","moa":"Mu-opioid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ National Drug Abuse Treatment CTN | The Emmes Company, LLC | Harvard Medical School (HMS and HSDM) | University of Pennsylvania | NYU Langone Health | Icahn School of Medicine at Mount Sinai | Alameda Health System | Weill Medical College of Cornell Unive","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ National Drug Abuse Treatment CTN | The Emmes Company, LLC | Harvard Medical School (HMS and HSDM) | University of Pennsylvania | NYU Langone Health | Icahn School of Medicine at Mount Sinai | Alameda Health System | Weill Medical College of Cornell Unive"},{"orgOrder":0,"company":"Anavex Life Sciences","sponsor":"COGNISION | Cognitive Research Corporation | Hassman Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ANAVEX3-71","moa":"Muscarinic acetylcholine receptor M1; Sigma non-opioid intracellular receptor 1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Anavex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Anavex Life Sciences \/ COGNISION | Cognitive Research Corporation | Hassman Research Institute","highestDevelopmentStatusID":"8","companyTruncated":"Anavex Life Sciences \/ COGNISION | Cognitive Research Corporation | Hassman Research Institute"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"VQW-765","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Vanda Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"VQW-765","moa":"nACh-alpha-7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vanda Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vanda Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vanda Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"ABT-126","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ABT-126","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"ABT-126","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"ABT-126","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"AQW051","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"AQW051","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Apeiron Biologics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Apeiron Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Apeiron Biologics"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Apeiron Investment Group"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Neuphoria Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Private Placement","leadProduct":"BNC210","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuphoria Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.070000000000000007,"dosageForm":"Tablet","sponsorNew":"Neuphoria Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"8","companyTruncated":"Neuphoria Therapeutics \/ Leerink Partners"},{"orgOrder":0,"company":"Tangent Data Services","sponsor":"Johnson & Johnson","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"JNJ-39393406","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tangent Data Services","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tangent Data Services \/ Johnson & Johnson","highestDevelopmentStatusID":"8","companyTruncated":"Tangent Data Services \/ Johnson & Johnson"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"TC-5619","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TC-5619","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TC-5619","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"CP-601927","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Achieve Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cytisine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Achieve Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Achieve Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Achieve Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2012","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"McNeil AB","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Controlled Substance","year":"2010","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"McNeil AB","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"McNeil AB \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"McNeil AB \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Troche\/Lozenge","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"UConn Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2011","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"UConn Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"UConn Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"UConn Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Rose Research Center","sponsor":"National Institutes of Health | Food and Drug Administration | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2016","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Rose Research Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rose Research Center \/ National Institutes of Health | Food and Drug Administration | National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Rose Research Center \/ National Institutes of Health | Food and Drug Administration | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Jed E. Rose","sponsor":"Philip Morris USA, Inc | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Nicotine","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jed E. Rose","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Jed E. Rose \/ Philip Morris USA, Inc | National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Jed E. Rose \/ Philip Morris USA, Inc | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Johannes Gutenberg University Mainz","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johannes Gutenberg University Mainz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johannes Gutenberg University Mainz \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Johannes Gutenberg University Mainz \/ Pfizer Inc"},{"orgOrder":0,"company":"Stanford University","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Stanford University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Stanford University \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Stanford University \/ Pfizer Inc"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Pfizer Inc"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Pfizer Inc"},{"orgOrder":0,"company":"University of Oklahoma","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Varenicline Tartrate","moa":"Neuronal acetylcholine receptor; alpha4\/beta2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Oklahoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Oklahoma \/ Pfizer Inc","highestDevelopmentStatusID":"8","companyTruncated":"University of Oklahoma \/ Pfizer Inc"},{"orgOrder":0,"company":"Neuralstem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"NSI-189","moa":"Neurotrophic factor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neuralstem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neuralstem \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neuralstem \/ Undisclosed"},{"orgOrder":0,"company":"Plethora Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"PSD502","moa":"Nitric oxide","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Plethora Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Plethora Solutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Plethora Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Plethora Solutions","sponsor":"Bio-Kinetic Europe | Fortrea","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PSD502","moa":"Nitric oxide","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Plethora Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Plethora Solutions \/ Bio-Kinetic Europe | Fortrea","highestDevelopmentStatusID":"8","companyTruncated":"Plethora Solutions \/ Bio-Kinetic Europe | Fortrea"},{"orgOrder":0,"company":"Plethora Solutions","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"PSD502","moa":"Nitric oxide","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Plethora Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Plethora Solutions \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Plethora Solutions \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"CTP-692","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Concert Pharmaceuticals \/ Cognitive Research Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Deuterated D-serine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Concert Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2020","type":"Inapplicable","leadProduct":"Deuterated D-serine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Concert Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder for Solution","sponsorNew":"Concert Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Concert Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"EVT 101","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"GM-1020","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Precision For Medicine | IQVIA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Perception Neuroscience \/ Precision For Medicine | IQVIA","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Precision For Medicine | IQVIA"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"ATAI Life Sciences \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2021","type":"Agreement","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Apeiron Investment Group","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2020","type":"Series C Financing","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"ATAI Life Sciences \/ Apeiron Investment Group","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Apeiron Investment Group"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"IntroSpect Digital Therapeutics","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"IntroSpect Digital Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"IntroSpect Digital Therapeutics \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"IntroSpect Digital Therapeutics \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Perception Neuroscience \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Perception Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Perception Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Perception Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Perception Neuroscience","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Collaboration","leadProduct":"R-Ketamine","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Perception Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Perception Neuroscience \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Perception Neuroscience \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"SLS-002","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Seelos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"SLS-002","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seelos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seelos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Seelos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"National Institute of Mental Health","sponsor":"Taisho Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"TS-161","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute of Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Institute of Mental Health \/ Taisho Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"National Institute of Mental Health \/ Taisho Pharmaceutical"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"N-methyl-D-aspartate receptor (NMDAR)||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gate Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"N-methyl-D-aspartate receptor (NMDAR)||NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gate Neurosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Undisclosed"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gate Neurosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gate Neurosciences \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Beacon Biosignals"},{"orgOrder":0,"company":"Syndeio Biosciences","sponsor":"Catalio Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Financing","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Syndeio Biosciences","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.089999999999999997,"dosageForm":"Tablet","sponsorNew":"Syndeio Biosciences \/ Catalio Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Syndeio Biosciences \/ Catalio Capital Management"},{"orgOrder":0,"company":"Syndeio Biosciences","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Zelquistinel","moa":"NMDA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Syndeio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syndeio Biosciences \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"8","companyTruncated":"Syndeio Biosciences \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AVP-923-20","moa":"NMDA receptor\/5-HT3 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NBI-1070770","moa":"NMDA subunit-2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Neurocrine Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NBI-1070770","moa":"NMDA subunit-2B receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocrine Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Neurocrine Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocrine Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"Bayside Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nitrous Oxide","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bayside Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayside Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayside Health \/ Undisclosed"},{"orgOrder":0,"company":"biozeus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"BZ371A","moa":"NO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"biozeus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"biozeus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"biozeus \/ Undisclosed"},{"orgOrder":0,"company":"biozeus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"BZ371A","moa":"NO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"biozeus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Gel","sponsorNew":"biozeus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"biozeus \/ Undisclosed"},{"orgOrder":0,"company":"biozeus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BZ371A","moa":"NO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"biozeus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"biozeus \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"biozeus \/ Undisclosed"},{"orgOrder":0,"company":"biozeus","sponsor":"Azidus Brazil","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"BZ371A","moa":"NO","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"biozeus","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"biozeus \/ Azidus Brazil","highestDevelopmentStatusID":"8","companyTruncated":"biozeus \/ Azidus Brazil"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"LY-2940094","moa":"Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BlackThorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"LY-2940094","moa":"Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlackThorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"LY-2940094","moa":"Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlackThorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"BlackThorn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"LY-2940094","moa":"Nociceptin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BlackThorn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BlackThorn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BlackThorn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Fasoracetam","moa":"nootropes (piracetam type)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Aevi Genomic Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Fasoracetam","moa":"nootropes (piracetam type)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aevi Genomic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevi Genomic Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aevi Genomic Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Purdue Pharmaceuticals L.P","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Purdue Pharmaceuticals L.P"},{"orgOrder":0,"company":"Imbrium Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sunobinop","moa":"NOP receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Imbrium Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Imbrium Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imbrium Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Theravance Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Ampreloxetine","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Theravance Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Theravance Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Theravance Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dexmethylphenidate","moa":"Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"BioLite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"PDC-1421","moa":"Norepinephrine transporter (NET)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioLite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioLite \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLite \/ Undisclosed"},{"orgOrder":0,"company":"BioLite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"PDC-1421","moa":"Norepinephrine transporter (NET)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioLite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioLite \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLite \/ Undisclosed"},{"orgOrder":0,"company":"BioLite","sponsor":"ABVC BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"PDC-1421","moa":"Norepinephrine transporter (NET)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioLite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioLite \/ ABVC BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"BioLite \/ ABVC BioPharma"},{"orgOrder":0,"company":"BioLite","sponsor":"American BriVision","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"PDC-1421","moa":"Norepinephrine transporter (NET)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioLite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioLite \/ American BriVision","highestDevelopmentStatusID":"8","companyTruncated":"BioLite \/ American BriVision"},{"orgOrder":0,"company":"BioLite","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PDC-1421","moa":"Norepinephrine transporter (NET)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"BioLite","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"BioLite \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"BioLite \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Ontario Mental Health Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2013","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Centre for Addiction and Mental Health \/ Ontario Mental Health Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Ontario Mental Health Foundation"},{"orgOrder":0,"company":"The Royal Ottawa Mental Health Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Methylphenidate","moa":"Norepinephrine transporter | Dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"The Royal Ottawa Mental Health Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The Royal Ottawa Mental Health Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"The Royal Ottawa Mental Health Centre \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"AVP-786","moa":"Opioid receptor sigma 1 (OPRS1)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"University of Washington","sponsor":"National Institute on Alcohol Abuse and Alcoholism | Alkermes Plc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Washington","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Washington \/ National Institute on Alcohol Abuse and Alcoholism | Alkermes Plc","highestDevelopmentStatusID":"8","companyTruncated":"University of Washington \/ National Institute on Alcohol Abuse and Alcoholism | Alkermes Plc"},{"orgOrder":0,"company":"Currax","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"Currax \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Currax \/ Undisclosed"},{"orgOrder":0,"company":"Shenzhen ScienCare Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu|kappa|delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shenzhen ScienCare Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shenzhen ScienCare Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shenzhen ScienCare Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"San Francisco Dept. of Public Health","sponsor":"Alkermes Plc | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"San Francisco Dept. of Public Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Extended Release","sponsorNew":"San Francisco Dept. of Public Health \/ Alkermes Plc | National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"San Francisco Dept. of Public Health \/ Alkermes Plc | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Go Medical Industries","sponsor":"National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | The Emmes Company, LLC | University at Buffalo","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Go Medical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Go Medical Industries \/ National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | The Emmes Company, LLC | University at Buffalo","highestDevelopmentStatusID":"8","companyTruncated":"Go Medical Industries \/ National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | The Emmes Company, LLC | University at Buffalo"},{"orgOrder":0,"company":"Go Medical Industries","sponsor":"National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Go Medical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Implant","sponsorNew":"Go Medical Industries \/ National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | Clinilabs","highestDevelopmentStatusID":"8","companyTruncated":"Go Medical Industries \/ National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | Clinilabs"},{"orgOrder":0,"company":"Go Medical Industries","sponsor":"National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | Clinilabs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Naltrexone","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Go Medical Industries","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Go Medical Industries \/ National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | Clinilabs","highestDevelopmentStatusID":"8","companyTruncated":"Go Medical Industries \/ National Institute on Drug Abuse | New York State Psychiatric Institute | Columbia University | Clinilabs"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Icalcaprant","moa":"OPRK1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Filorexant","moa":"Orexin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"University of California, Los Angeles | University of Texas Health Science Center at Houston","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Suvorexant","moa":"Orexin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ University of California, Los Angeles | University of Texas Health Science Center at Houston","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ University of California, Los Angeles | University of Texas Health Science Center at Houston"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"University of Toronto | Centre for Addiction and Mental Health | Toronto Metropolitan University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Lemborexant","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Unity Health Toronto \/ University of Toronto | Centre for Addiction and Mental Health | Toronto Metropolitan University","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ University of Toronto | Centre for Addiction and Mental Health | Toronto Metropolitan University"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ACT-539313","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Idorsia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ACT-539313","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Idorsia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Idorsia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Idorsia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"JNJ-61393215","moa":"OX1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Indivior \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Indivior","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Powder in Capsule","sponsorNew":"Indivior \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"INDV-2000","moa":"OX2 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"San Diego Veterans Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"San Diego Veterans Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"San Diego Veterans Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"San Diego Veterans Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"San Francisco VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"VA Office of Research and Development \/ San Francisco VA Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ San Francisco VA Health Care System"},{"orgOrder":0,"company":"VA Office of Research and Development","sponsor":"University of California, San Francisco | VA Greater Los Angeles Healthcare System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Office of Research and Development","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Office of Research and Development \/ University of California, San Francisco | VA Greater Los Angeles Healthcare System","highestDevelopmentStatusID":"8","companyTruncated":"VA Office of Research and Development \/ University of California, San Francisco | VA Greater Los Angeles Healthcare System"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Harvard Medical School","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Collaboration","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Harvard Medical School"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"University of Washington","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2023","type":"Agreement","leadProduct":"Oxytocin","moa":"Oxytocin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ University of Washington","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ University of Washington"},{"orgOrder":0,"company":"CCTU-Core","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"JNJ-54175446","moa":"P2X purinoceptor 7","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"CCTU-Core","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"CCTU-Core \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"8","companyTruncated":"CCTU-Core \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"JNJ-55308942","moa":"P2X7 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"National Center for Research and Development, Poland","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"CPL500036","moa":"PDE10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celon Pharma \/ National Center for Research and Development, Poland","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ National Center for Research and Development, Poland"},{"orgOrder":0,"company":"Celon Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"POLAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"CPL500036","moa":"PDE10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Celon Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Celon Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Celon Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-101","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Alto Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ALTO-101","moa":"PDE4","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Alto Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Alto Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Alto Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"Strategic Science & Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"SST-6007","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Strategic Science & Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Strategic Science & Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Strategic Science & Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"IPED2015","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Initiator Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Initiator Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IPED2015","moa":"PDE5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Initiator Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Initiator Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"BI409306","moa":"PDE9A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Gemfibrozil","moa":"Peroxisome proliferator-activated receptor alpha","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Omeros","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Pioglitazone","moa":"Peroxisome proliferator-activated receptor gamma","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Omeros","highestDevelopmentStatusID":"8","companyTruncated":"New York State Psychiatric Institute \/ Omeros"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Omega-3 Polyunsaturated Fatty Acids","moa":"Peroxisome proliferator-activated receptor gamma; Peroxisome proliferator-activated receptor alpha; Sterol regulatory element-binding protein 1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"PF-02545920","moa":"Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PF-02545920","moa":"Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PF-02545920","moa":"Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"TAK-063","moa":"Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"TAK-063","moa":"Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lu AF11167","moa":"Phosphodiesterase 10A (PDE10)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"Strategic Science & Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Strategic Science & Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Strategic Science & Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Strategic Science & Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Strategic Science & Technologies","sponsor":"Dar\u00e9 Bioscience","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Strategic Science & Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Strategic Science & Technologies \/ Dar\u00e9 Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Strategic Science & Technologies \/ Dar\u00e9 Bioscience"},{"orgOrder":0,"company":"Emotional Brain NY","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Emotional Brain NY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emotional Brain NY \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Emotional Brain NY \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Strategic Science & Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Strategic Science & Technologies"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Lincoln Park Capital Fund","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.02,"dosageForm":"Cream","sponsorNew":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund","highestDevelopmentStatusID":"8","companyTruncated":"Dar\u00e9 Bioscience \/ Lincoln Park Capital Fund"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Takeda Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Udenafil","moa":"Phosphodiesterase 5A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Takeda Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Takeda Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Takeda Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"National Institute on Alcohol Abuse and Alcoholism | Medicinova","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of California, Los Angeles \/ National Institute on Alcohol Abuse and Alcoholism | Medicinova","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ National Institute on Alcohol Abuse and Alcoholism | Medicinova"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"National Institute on Drug Abuse | Medicinova","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ National Institute on Drug Abuse | Medicinova","highestDevelopmentStatusID":"8","companyTruncated":"New York State Psychiatric Institute \/ National Institute on Drug Abuse | Medicinova"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"UCLA","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ UCLA","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ UCLA"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Medicinova","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibudilast","moa":"Phosphodiesterase 5A | Phosphodiesterase 3A | Phosphodiesterase 4 | Phosphodiesterase 10A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medicinova","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Medicinova \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medicinova \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BI 409306","moa":"Phosphodiesterase 9A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"BI 409306","moa":"Phosphodiesterase 9A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"BI 409306","moa":"Phosphodiesterase 9A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"BI 409306","moa":"Phosphodiesterase 9A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Canadian College of Naturopathic Medicine","sponsor":"McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Omega-3","moa":"PPA-gamma receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canadian College of Naturopathic Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Canadian College of Naturopathic Medicine \/ McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs","highestDevelopmentStatusID":"8","companyTruncated":"Canadian College of Naturopathic Medicine \/ McGill University | Netherlands Open University | Massachusetts General Hospital | Ekhagastiftelsen | AquaOmega | Lipid Analytical Laboratories | Mitacs"},{"orgOrder":0,"company":"Aldeyra Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ADX\u2011629","moa":"RASP","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aldeyra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aldeyra Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aldeyra Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Ohio State University","sponsor":"Acadia Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ohio State University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ohio State University \/ Acadia Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Ohio State University \/ Acadia Pharmaceuticals"},{"orgOrder":0,"company":"Acadia Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Pimavanserin Tartrate","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acadia Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acadia Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acadia Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Filament Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University Hospital Ghent \/ Filament Health","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Ghent \/ Filament Health"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Beersheva Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beersheva Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beersheva Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beersheva Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Compass Pathways","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Diego \/ Compass Pathways"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Queen's University","sponsor":"Diamond Therapeutics | Kingston Health Sciences Centre","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Queen's University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Queen's University \/ Diamond Therapeutics | Kingston Health Sciences Centre","highestDevelopmentStatusID":"8","companyTruncated":"Queen's University \/ Diamond Therapeutics | Kingston Health Sciences Centre"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunnybrook Health Sciences Centre \/ Undisclosed"},{"orgOrder":0,"company":"University Health Network, Toronto","sponsor":"Centre for Addiction and Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University Health Network, Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University Health Network, Toronto \/ Centre for Addiction and Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"University Health Network, Toronto \/ Centre for Addiction and Mental Health"},{"orgOrder":0,"company":"Unity Health Toronto","sponsor":"Toronto Metropolitan University | University of Ottawa","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Unity Health Toronto","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unity Health Toronto \/ Toronto Metropolitan University | University of Ottawa","highestDevelopmentStatusID":"8","companyTruncated":"Unity Health Toronto \/ Toronto Metropolitan University | University of Ottawa"},{"orgOrder":0,"company":"Brain and Cognition Discovery Foundation","sponsor":"Braxia Scientific Corp. | Usona Institute","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Brain and Cognition Discovery Foundation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Brain and Cognition Discovery Foundation \/ Braxia Scientific Corp. | Usona Institute","highestDevelopmentStatusID":"8","companyTruncated":"Brain and Cognition Discovery Foundation \/ Braxia Scientific Corp. | Usona Institute"},{"orgOrder":0,"company":"Sheppard Pratt Health System","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sheppard Pratt Health System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sheppard Pratt Health System \/ Compass Pathways","highestDevelopmentStatusID":"8","companyTruncated":"Sheppard Pratt Health System \/ Compass Pathways"},{"orgOrder":0,"company":"Sheppard Pratt Health System","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sheppard Pratt Health System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sheppard Pratt Health System \/ Compass Pathways","highestDevelopmentStatusID":"8","companyTruncated":"Sheppard Pratt Health System \/ Compass Pathways"},{"orgOrder":0,"company":"Sheppard Pratt Health System","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sheppard Pratt Health System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sheppard Pratt Health System \/ Compass Pathways","highestDevelopmentStatusID":"8","companyTruncated":"Sheppard Pratt Health System \/ Compass Pathways"},{"orgOrder":0,"company":"New York State Psychiatric Institute","sponsor":"Compass Pathways | University of California, Los Angeles","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"New York State Psychiatric Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New York State Psychiatric Institute \/ Compass Pathways | University of California, Los Angeles","highestDevelopmentStatusID":"8","companyTruncated":"New York State Psychiatric Institute \/ Compass Pathways | University of California, Los Angeles"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Heffter Research Institute | University of New Mexico","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Heffter Research Institute | University of New Mexico","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Heffter Research Institute | University of New Mexico"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Usona Institute","sponsor":"The Emmes Company, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Usona Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Usona Institute \/ The Emmes Company, LLC","highestDevelopmentStatusID":"8","companyTruncated":"Usona Institute \/ The Emmes Company, LLC"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Optimapharm","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Optimapharm","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Optimapharm"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Halucenex Life Sciences \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ KGK Science"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Compass Pathways","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Compass Pathways","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Compass Pathways"},{"orgOrder":0,"company":"Cybin","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Cybin","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cybin \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Cybin \/ Undisclosed"},{"orgOrder":0,"company":"Baylor College of Medicine","sponsor":"Texas Department of State Health Services | Usona Institute | AIM Youth Mental Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Baylor College of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baylor College of Medicine \/ Texas Department of State Health Services | Usona Institute | AIM Youth Mental Health","highestDevelopmentStatusID":"8","companyTruncated":"Baylor College of Medicine \/ Texas Department of State Health Services | Usona Institute | AIM Youth Mental Health"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"University of Sydney","sponsor":"Woke Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Sydney","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sydney \/ Woke Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Sydney \/ Woke Pharmaceuticals"},{"orgOrder":0,"company":"Yvan Beaussant, MD, MSci","sponsor":"Cy Biopharma | Pancreatic Cancer North America","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yvan Beaussant, MD, MSci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yvan Beaussant, MD, MSci \/ Cy Biopharma | Pancreatic Cancer North America","highestDevelopmentStatusID":"8","companyTruncated":"Yvan Beaussant, MD, MSci \/ Cy Biopharma | Pancreatic Cancer North America"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"ATAI Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2020","type":"Series B Financing","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.080000000000000002,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ ATAI Life Sciences","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ ATAI Life Sciences"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Compass Pathways \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Undisclosed"},{"orgOrder":0,"company":"Compass Pathways","sponsor":"Kings College London","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Compass Pathways","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Compass Pathways \/ Kings College London","highestDevelopmentStatusID":"8","companyTruncated":"Compass Pathways \/ Kings College London"},{"orgOrder":0,"company":"Psyence","sponsor":"Newcourt Acquisition Corp","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Merger","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Newcourt Acquisition Corp","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Newcourt Acquisition Corp"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Sunstone Therapies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sunstone Therapies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sunstone Therapies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sunstone Therapies \/ Undisclosed"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Ingenu","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Partnership","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ingenu","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ingenu \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Ingenu \/ Psyence"},{"orgOrder":0,"company":"Psyence","sponsor":"Cantheon Capital","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Cantheon Capital","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Cantheon Capital"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence \/ Undisclosed"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence Biomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Undisclosed"},{"orgOrder":0,"company":"Psyence Biomed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Psyence Biomed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Psyence Biomed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Psyence Biomed \/ Undisclosed"},{"orgOrder":0,"company":"SABI Mind","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"SABI Mind","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SABI Mind \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"SABI Mind \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clairvoyant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clairvoyant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Clairvoyant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clairvoyant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Origin Therapeutics","sponsor":"Clairvoyant Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Origin Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Origin Therapeutics \/ Clairvoyant Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Origin Therapeutics \/ Clairvoyant Therapeutics"},{"orgOrder":0,"company":"Filament Health","sponsor":"Psyence","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Filament Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Filament Health \/ Psyence","highestDevelopmentStatusID":"8","companyTruncated":"Filament Health \/ Psyence"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Braxia Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"University of Florida","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ University of Florida","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ University of Florida"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Westar Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Westar Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Westar Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Braxia Scientific \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Undisclosed"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Alto Capital Limited","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Alto Capital Limited","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Alto Capital Limited"},{"orgOrder":0,"company":"Tryp Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tryp Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Tryp Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tryp Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Halucenex Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Halucenex Life Sciences","sponsor":"Everest Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Halucenex Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Halucenex Life Sciences \/ Everest Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Halucenex Life Sciences \/ Everest Clinical Research"},{"orgOrder":0,"company":"Catalent Pharma Solutions","sponsor":"Incannex Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Catalent Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Catalent Pharma Solutions \/ Incannex Healthcare","highestDevelopmentStatusID":"8","companyTruncated":"Catalent Pharma Solutions \/ Incannex Healthcare"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Braxia Scientific","sponsor":"Brain and Cognition Discovery Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Braxia Scientific","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Braxia Scientific \/ Brain and Cognition Discovery Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Braxia Scientific \/ Brain and Cognition Discovery Foundation"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incannex Healthcare \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Undisclosed"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Monash University","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2022","type":"Licensing Agreement","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incannex Healthcare \/ Monash University","highestDevelopmentStatusID":"8","companyTruncated":"Incannex Healthcare \/ Monash University"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"US Department of Defense | Tonix Pharmaceuticals Holding Corp | McLean Hospital | Cooper University Health Care","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Cyclobenzaprine","moa":"Serotonin 2a (5-HT2a) receptor | Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of North Carolina \/ US Department of Defense | Tonix Pharmaceuticals Holding Corp | McLean Hospital | Cooper University Health Care","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ US Department of Defense | Tonix Pharmaceuticals Holding Corp | McLean Hospital | Cooper University Health Care"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Lorcaserin HCl","moa":"Serotonin 2c (5-HT2c) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Transcept Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Ondansetron","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Transcept Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Transcept Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Transcept Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Seoul National University Hospital","sponsor":"H. Lundbeck AS","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seoul National University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Seoul National University Hospital \/ H. Lundbeck AS","highestDevelopmentStatusID":"8","companyTruncated":"Seoul National University Hospital \/ H. Lundbeck AS"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"H. Lundbeck AS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"H. Lundbeck AS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"H. Lundbeck AS \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"H. Lundbeck AS \/ Undisclosed"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Vortioxetine Hydrobromide","moa":"Serotonin 3a (5-HT3a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"University of Chicago \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"University of Chicago \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Johns Hopkins University","sponsor":"Forest Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Escitalopram Oxalate","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johns Hopkins University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johns Hopkins University \/ Forest Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Johns Hopkins University \/ Forest Laboratories"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fluoxetine Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Seventh People's Hospital of Hangzhou | First Affiliated Hospital of Kunming Medical University | General Hospital of Ningxia Medical University | The First Affiliated Hospital of Nanchang University | The Second Affiliated Hospital of Xinxiang Medical Un"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Sertraline Hydrochloride","moa":"Serotonin transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Global Coalition for Adaptive Research","sponsor":"U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Vilazodone Hydrochloride","moa":"Serotonin transporter | Serotonin 1a (5-HT1a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Global Coalition for Adaptive Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline","highestDevelopmentStatusID":"8","companyTruncated":"Global Coalition for Adaptive Research \/ U.S. Army Medical Research and Development Command | PPD | Berry Consultants | Idorsia Pharmaceuticals | Cambridge Cognition | Citeline"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Rho Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"TNX-601 ER","moa":"Serotonin\/norepinephrine reuptake","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Rho Inc","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Rho Inc"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"OPC-64005","moa":"Serotoninnorepinephrinedopamine reuptake (SNDR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"OPC-64005","moa":"Serotoninnorepinephrinedopamine reuptake (SNDR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Otsuka Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Dong-A Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"DA-8031","moa":"SERT","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dong-A Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dong-A Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dong-A Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BAY60-4552","moa":"sGC","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"BAY60-4552","moa":"sGC","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"Yale University","sponsor":"Connecticut Mental Health Center","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yale University \/ Connecticut Mental Health Center","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Connecticut Mental Health Center"},{"orgOrder":0,"company":"University of Sydney","sponsor":"Monash University | Sydney Local Health District","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Sydney","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Sydney \/ Monash University | Sydney Local Health District","highestDevelopmentStatusID":"8","companyTruncated":"University of Sydney \/ Monash University | Sydney Local Health District"},{"orgOrder":0,"company":"Patricia Suppes","sponsor":"Stanford University | VA Palo Alto Health Care System | Steven & Alexandra Cohen Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Patricia Suppes","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Patricia Suppes \/ Stanford University | VA Palo Alto Health Care System | Steven & Alexandra Cohen Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Patricia Suppes \/ Stanford University | VA Palo Alto Health Care System | Steven & Alexandra Cohen Foundation"},{"orgOrder":0,"company":"Remedy","sponsor":"Multidisciplinary Association for Psychedelic Studies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Remedy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy \/ Multidisciplinary Association for Psychedelic Studies","highestDevelopmentStatusID":"8","companyTruncated":"Remedy \/ Multidisciplinary Association for Psychedelic Studies"},{"orgOrder":0,"company":"Remedy","sponsor":"Remedy Institute","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Remedy","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Remedy \/ Remedy Institute","highestDevelopmentStatusID":"8","companyTruncated":"Remedy \/ Remedy Institute"},{"orgOrder":0,"company":"VA Loma Linda Health Care System","sponsor":"Multidisciplinary Association for Psychedelic Studies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2||Synaptic vesicular amine transporter; Sodium-dependent noradrenaline transporter; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2A; 5-hydroxytryptamine receptor 2B; Sodium-dependent dopamine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Loma Linda Health Care System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Loma Linda Health Care System \/ Multidisciplinary Association for Psychedelic Studies","highestDevelopmentStatusID":"8","companyTruncated":"VA Loma Linda Health Care System \/ Multidisciplinary Association for Psychedelic Studies"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Private Placement","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Private Placement","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ Undisclosed"},{"orgOrder":0,"company":"PharmAla Biotech","sponsor":"University of Sydney","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PharmAla Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PharmAla Biotech \/ University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"PharmAla Biotech \/ University of Sydney"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Midomafetamine","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Lundquist Institute for Biomedical Innovation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Lundquist Institute for Biomedical Innovation","highestDevelopmentStatusID":"8","companyTruncated":"Lykos Therapeutics \/ Lundquist Institute for Biomedical Innovation"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"MAPS Europe","sponsor":"Multidisciplinary Association for Psychedelic Studies","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Midomafetamine HCl","moa":"SLC18A2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MAPS Europe","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MAPS Europe \/ Multidisciplinary Association for Psychedelic Studies","highestDevelopmentStatusID":"8","companyTruncated":"MAPS Europe \/ Multidisciplinary Association for Psychedelic Studies"},{"orgOrder":0,"company":"Bial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"PORTUGAL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Undisclosed"},{"orgOrder":0,"company":"Bial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"PORTUGAL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Undisclosed"},{"orgOrder":0,"company":"Bial","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"PORTUGAL","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Eslicarbazepine Acetate","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bial","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Bial \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bial \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Newron Pharmaceuticals","sponsor":"Myung In Pharm","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Licensing Agreement","leadProduct":"Evenamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Newron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Newron Pharmaceuticals \/ Myung In Pharm","highestDevelopmentStatusID":"8","companyTruncated":"Newron Pharmaceuticals \/ Myung In Pharm"},{"orgOrder":0,"company":"University of California, San Francisco","sponsor":"San Francisco VA Health Care System","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California, San Francisco","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Francisco \/ San Francisco VA Health Care System","highestDevelopmentStatusID":"8","companyTruncated":"University of California, San Francisco \/ San Francisco VA Health Care System"},{"orgOrder":0,"company":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","sponsor":"Congressionally Directed Medical Research Programs | Michael E. DeBakey VA Medical Center | Baylor College of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Zonisamide","moa":"Sodium channel alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ Congressionally Directed Medical Research Programs | Michael E. DeBakey VA Medical Center | Baylor College of Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Pharmacotherapies for Alcohol and Substance Use Disorders Alliance \/ Congressionally Directed Medical Research Programs | Michael E. DeBakey VA Medical Center | Baylor College of Medicine"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"American Society of Clinical Psychopharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Empagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ American Society of Clinical Psychopharmacology","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ American Society of Clinical Psychopharmacology"},{"orgOrder":0,"company":"Futura Medical","sponsor":"Richmond Pharmacology","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Nitroglycerin","moa":"Soluble guanylate cyclase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Futura Medical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Futura Medical \/ Richmond Pharmacology","highestDevelopmentStatusID":"8","companyTruncated":"Futura Medical \/ Richmond Pharmacology"},{"orgOrder":0,"company":"US Department of Defense","sponsor":"GSK","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Omega-3-Acid Ethyl Esters 90","moa":"steroids (androgens","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"US Department of Defense","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"US Department of Defense \/ GSK","highestDevelopmentStatusID":"8","companyTruncated":"US Department of Defense \/ GSK"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"National Institute of Mental Health | Institute for Medical Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pregnenolone","moa":"steroids (not prednisolone derivatives)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ National Institute of Mental Health | Institute for Medical Research, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ National Institute of Mental Health | Institute for Medical Research, Inc."},{"orgOrder":0,"company":"Spinogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synapses","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spinogenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Undisclosed"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"SPG302","moa":"Synapses","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spinogenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Undisclosed"},{"orgOrder":0,"company":"Spinogenix","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"SPG302","moa":"Synapses","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Spinogenix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Spinogenix \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Spinogenix \/ Undisclosed"},{"orgOrder":0,"company":"University of California, Los Angeles","sponsor":"National Institute of Mental Health | SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of California, Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, Los Angeles \/ National Institute of Mental Health | SHIRE PLC","highestDevelopmentStatusID":"8","companyTruncated":"University of California, Los Angeles \/ National Institute of Mental Health | SHIRE PLC"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"SHIRE PLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ SHIRE PLC","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ SHIRE PLC"},{"orgOrder":0,"company":"Yale University","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Yale University \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Yale University \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Valbenazine Tosylate","moa":"Synaptic vesicular amine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Chicago \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"University of Chicago \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Aaron Keshen","sponsor":"Nova Scotia Health Authority","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Lisdexamfetamine Dimesylate","moa":"Synaptic vesicular amine transporter | Dopamine transporter | Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aaron Keshen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aaron Keshen \/ Nova Scotia Health Authority","highestDevelopmentStatusID":"8","companyTruncated":"Aaron Keshen \/ Nova Scotia Health Authority"},{"orgOrder":0,"company":"INmune Bio","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Protein","year":"2020","type":"Funding","leadProduct":"Pegipanermin","moa":"TNF receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"INmune Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"INmune Bio \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"INmune Bio \/ National Institutes of Health"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"ABX-002","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"ABX-002","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Novotech","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ABX-002","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Autobahn Therapeutics \/ Novotech","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Novotech"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Arch Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Arch Ventures"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Canaan Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Canaan Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Canaan Partners"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Newpath Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series C Financing","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.10000000000000001,"dosageForm":"Capsule","sponsorNew":"Autobahn Therapeutics \/ Newpath Partners","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Newpath Partners"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Autobahn Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Methyl Amide Prodrug","moa":"TR-beta","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Autobahn Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Autobahn Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Autobahn Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Honeybrains Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Telmisartan","moa":"Type-1 angiotensin II receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Honeybrains Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Honeybrains Biotech \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Honeybrains Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Yamo Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2016","type":"Inapplicable","leadProduct":"Methyltyrosine","moa":"Tyrosine hydroxylase","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yamo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yamo Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yamo Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"UConn Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Dasatinib","moa":"Tyrosine-protein kinase ABL | Bcr\/Abl fusion protein | Platelet-derived growth factor receptor beta | Ephrin type-A receptor 2 | SRC | Stem cell growth factor receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Washington University School of Medicine \/ UConn Health","highestDevelopmentStatusID":"8","companyTruncated":"Washington University School of Medicine \/ UConn Health"},{"orgOrder":0,"company":"Scripps Research","sponsor":"National Institute on Alcohol Abuse and Alcoholism | Mapreg","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MAP4343","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Scripps Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scripps Research \/ National Institute on Alcohol Abuse and Alcoholism | Mapreg","highestDevelopmentStatusID":"8","companyTruncated":"Scripps Research \/ National Institute on Alcohol Abuse and Alcoholism | Mapreg"},{"orgOrder":0,"company":"Emory University","sponsor":"MAPS","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"3,4-Methylenedioxymethamphetamine HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Emory University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Emory University \/ MAPS","highestDevelopmentStatusID":"8","companyTruncated":"Emory University \/ MAPS"},{"orgOrder":0,"company":"Lykos Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"3,4-Methylenedioxymethamphetamine HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Lykos Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lykos Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Lykos Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sumitomo Pharma America","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"36404","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sumitomo Pharma America","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sumitomo Pharma America \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sumitomo Pharma America \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ABBV-932","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ABBV-932","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Gedeon Richter","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-932","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Gedeon Richter","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Gedeon Richter"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"ABBV-932","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"Afasci","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AFA-281","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Afasci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Afasci \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Afasci \/ Undisclosed"},{"orgOrder":0,"company":"Afasci","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"AFA-281","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Afasci","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Afasci \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Afasci \/ Undisclosed"},{"orgOrder":0,"company":"Zylorion Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Almond","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Zylorion Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zylorion Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Zylorion Health \/ Undisclosed"},{"orgOrder":0,"company":"Ethical Naturals, Inc.","sponsor":"KGK Science","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2023","type":"Inapplicable","leadProduct":"Alphawave L-Theanine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ethical Naturals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethical Naturals, Inc. \/ KGK Science","highestDevelopmentStatusID":"8","companyTruncated":"Ethical Naturals, Inc. \/ KGK Science"},{"orgOrder":0,"company":"Ethical Naturals, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Amino Acid","year":"2021","type":"Inapplicable","leadProduct":"Alphawave L-Theanine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ethical Naturals, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ethical Naturals, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ethical Naturals, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AMG747","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"AMG747","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Undisclosed"},{"orgOrder":0,"company":"CSPC ZhongQi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Ammoxetine HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"CSPC ZhongQi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"CSPC ZhongQi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"CSPC ZhongQi \/ Undisclosed"},{"orgOrder":0,"company":"Ancora Bio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"ANC-501","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ancora Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ancora Bio \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ancora Bio \/ Undisclosed"},{"orgOrder":0,"company":"Apex Labs","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"APEX-002-A02","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Apex Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apex Labs \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apex Labs \/ Undisclosed"},{"orgOrder":0,"company":"Aphios","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"APH-1501","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Aphios","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection, Powder, Lyophilized","sponsorNew":"Aphios \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Aphios \/ Undisclosed"},{"orgOrder":0,"company":"Natreon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"Ashwagandha","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Natreon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natreon \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Natreon \/ Undisclosed"},{"orgOrder":0,"company":"Pharmicell Co., Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Autologous Bone Marrow-Derived Msc","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pharmicell Co., Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmicell Co., Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmicell Co., Inc \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2015","type":"Inapplicable","leadProduct":"Avena Sativa","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Avena Sativa","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"Heel","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Plant Extract\/Herbal","year":"2012","type":"Inapplicable","leadProduct":"Avena Sativa","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Heel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Heel \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heel \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bear Bile","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BI1358894","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BI1358894","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"BI1358894","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"BI1358894","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BI1358894","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Vinmec Healthcare System","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"VIETNAM","productType":"Cell & Gene Therapy","year":"2015","type":"Inapplicable","leadProduct":"Bone Marrow Mononuclear Cell","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vinmec Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vinmec Healthcare System \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vinmec Healthcare System \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"BP1.3656","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"CTC Bio","sponsor":"SYMYOO Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"CDFR0812","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"CTC Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CTC Bio \/ SYMYOO Inc","highestDevelopmentStatusID":"8","companyTruncated":"CTC Bio \/ SYMYOO Inc"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ITALY","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHF6563","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chiesi Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chiesi Group \/ Undisclosed"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"University of Arkansas","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"CHI-554","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oil","sponsorNew":"Canopy Growth Corporation \/ University of Arkansas","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ University of Arkansas"},{"orgOrder":0,"company":"Canopy Growth Corporation","sponsor":"Centre for Addiction and Mental Health | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CHI-902","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Canopy Growth Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Liquid","sponsorNew":"Canopy Growth Corporation \/ Centre for Addiction and Mental Health | McMaster University","highestDevelopmentStatusID":"8","companyTruncated":"Canopy Growth Corporation \/ Centre for Addiction and Mental Health | McMaster University"},{"orgOrder":0,"company":"Clexio Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"CLE-100","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clexio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clexio Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clexio Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Clexio Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"CLE-100","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Clexio Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Clexio Biosciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Clexio Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"National Institute on Drug Abuse","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Agreement","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ National Institute on Drug Abuse"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2024","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Enzyme","year":"2022","type":"Inapplicable","leadProduct":"Cocaine Esterase","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Undisclosed"},{"orgOrder":0,"company":"Sutter Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Cord Blood Stem Cell","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sutter Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Sutter Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sutter Health \/ Undisclosed"},{"orgOrder":0,"company":"Chrono Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"CQSS2","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chrono Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chrono Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chrono Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Otsuka Holdings","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"d6-Dextromethorphan HBr","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Otsuka Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Otsuka Holdings \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Otsuka Holdings \/ Undisclosed"},{"orgOrder":0,"company":"Teikoku Pharma USA","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"DMTS","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Teikoku Pharma USA","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Patch","sponsorNew":"Teikoku Pharma USA \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Teikoku Pharma USA \/ Undisclosed"},{"orgOrder":0,"company":"Europharma","sponsor":"Simon Khechinashvili University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2018","type":"Inapplicable","leadProduct":"Echinacea Angustifolia","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Europharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Europharma \/ Simon Khechinashvili University","highestDevelopmentStatusID":"8","companyTruncated":"Europharma \/ Simon Khechinashvili University"},{"orgOrder":0,"company":"Gilgamesh Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GM-2505","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gilgamesh Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilgamesh Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Gilgamesh Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Greatway Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GW117","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beijing Greatway Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Beijing Greatway Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Greatway Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Beijing Greatway Pharmaceutical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GW117","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beijing Greatway Pharmaceutical Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beijing Greatway Pharmaceutical Technology \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beijing Greatway Pharmaceutical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Besancon","sponsor":"Fondation FondaMental | GYNOV","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GynMDD","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Besancon","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier Universitaire de Besancon \/ Fondation FondaMental | GYNOV","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Besancon \/ Fondation FondaMental | GYNOV"},{"orgOrder":0,"company":"Honeybrains Biotech","sponsor":"Cognitive Research Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Honeybrains Biotech","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Honeybrains Biotech \/ Cognitive Research Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Honeybrains Biotech \/ Cognitive Research Corporation"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"HLD100","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironshore Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Ironshore Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"HLD100","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ironshore Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ironshore Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ironshore Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10353","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"HS-10353","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"HS-10353","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Hansoh Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Hansoh Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Initiator Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"IP2018","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Initiator Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Initiator Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Initiator Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Ixchelsis","sponsor":"Carelon Research | Novotech | Icon Plc | PHT Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"IX-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ixchelsis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ixchelsis \/ Carelon Research | Novotech | Icon Plc | PHT Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Ixchelsis \/ Carelon Research | Novotech | Icon Plc | PHT Corporation"},{"orgOrder":0,"company":"Ixchelsis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"IX-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ixchelsis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ixchelsis \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ixchelsis \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"JNJ-26489112","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"JNJ-89495120","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Tianjin Tasly Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"JS1-1-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Tianjin Tasly Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Tianjin Tasly Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Tianjin Tasly Group \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KH607","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Kanghong Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"KH607","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Chengdu Kanghong Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Chengdu Kanghong Pharmaceutical Group \/ Undisclosed"},{"orgOrder":0,"company":"VA Eastern Colorado Health Care System","sponsor":"University of Colorado, Denver | University of Colorado, Boulder","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Probiotic","year":"2019","type":"Inapplicable","leadProduct":"Lactobacillus Rhamnosus GG","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"VA Eastern Colorado Health Care System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VA Eastern Colorado Health Care System \/ University of Colorado, Denver | University of Colorado, Boulder","highestDevelopmentStatusID":"8","companyTruncated":"VA Eastern Colorado Health Care System \/ University of Colorado, Denver | University of Colorado, Boulder"},{"orgOrder":0,"company":"Centre Hospitalier de l'Universite de Montreal","sponsor":"Ministere de la Sante et des Services Sociaux | Health Canada","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LDX-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre Hospitalier de l'Universite de Montreal","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre Hospitalier de l'Universite de Montreal \/ Ministere de la Sante et des Services Sociaux | Health Canada","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier de l'Universite de Montreal \/ Ministere de la Sante et des Services Sociaux | Health Canada"},{"orgOrder":0,"company":"Dicot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LIB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dicot","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dicot \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dicot \/ Undisclosed"},{"orgOrder":0,"company":"Dicot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"LIB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dicot","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dicot \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dicot \/ Undisclosed"},{"orgOrder":0,"company":"Dicot","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"LIB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Dicot","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Dicot \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Dicot \/ Undisclosed"},{"orgOrder":0,"company":"Massachusetts General Hospital","sponsor":"Neurocentria","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2015","type":"Inapplicable","leadProduct":"Magnesium L-Threonate","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Massachusetts General Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Massachusetts General Hospital \/ Neurocentria","highestDevelopmentStatusID":"8","companyTruncated":"Massachusetts General Hospital \/ Neurocentria"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"LV232","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Vigonvita Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SINGAPORE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"LV232","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Vigonvita Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Vigonvita Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Vigonvita Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Mapreg","sponsor":"Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"MAP4343","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Mapreg","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mapreg \/ Eurofins CDMO","highestDevelopmentStatusID":"8","companyTruncated":"Mapreg \/ Eurofins CDMO"},{"orgOrder":0,"company":"Nova Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"VIETNAM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MI078","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Nova Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nova Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nova Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nova Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"VIETNAM","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"MI078","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Nova Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nova Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nova Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"MK-1942","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"MK-8189","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Merck & Co \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Merck & Co \/ Undisclosed"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Neurocentria | Brain & Behavior Research Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MMFS-202-302","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Pill","sponsorNew":"Northwestern University \/ Neurocentria | Brain & Behavior Research Foundation","highestDevelopmentStatusID":"8","companyTruncated":"Northwestern University \/ Neurocentria | Brain & Behavior Research Foundation"},{"orgOrder":0,"company":"Neurocentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Dietary Supplement","year":"2018","type":"Inapplicable","leadProduct":"MMFS-205-SR","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocentria \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"Motherwell","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Motherwell","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ Undisclosed"},{"orgOrder":0,"company":"MSI Methylation Sciences Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2013","type":"Inapplicable","leadProduct":"MSI-195","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MSI Methylation Sciences Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MSI Methylation Sciences Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MSI Methylation Sciences Inc \/ Undisclosed"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"National Health and Medical Research Council, Australia | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney","highestDevelopmentStatusID":"8","companyTruncated":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney"},{"orgOrder":0,"company":"Jiangsu Nhwa Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"NH102","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jiangsu Nhwa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Nhwa Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Nhwa Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Neumora therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NMRA-335140","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neumora therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neumora therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neumora therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"DuKang Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NORA520","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"DuKang Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"DuKang Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"DuKang Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Neurocentria","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"NRCT-101","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Neurocentria","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Neurocentria \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Neurocentria \/ Undisclosed"},{"orgOrder":0,"company":"Royal DSM","sponsor":"Abbott Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Nutritional Beverage Fortified With Lutein","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Royal DSM","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Royal DSM \/ Abbott Laboratories","highestDevelopmentStatusID":"8","companyTruncated":"Royal DSM \/ Abbott Laboratories"},{"orgOrder":0,"company":"Omeros","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"OMS643762","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Omeros","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Omeros \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Omeros \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ONO-1110","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"ONO-1110","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ono Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ono Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Kunming KingBio Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Plant Extract\/Herbal","year":"2014","type":"Inapplicable","leadProduct":"Orcinoside","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Kunming KingBio Biotechnology","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Kunming KingBio Biotechnology"},{"orgOrder":0,"company":"PleoPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"PP-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PleoPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PleoPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PleoPharma \/ Undisclosed"},{"orgOrder":0,"company":"LALLEMAND HEALTH SOLUTIONS","sponsor":"MedQualis | Q & T Research","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2015","type":"Inapplicable","leadProduct":"Probiotic L008-1","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"LALLEMAND HEALTH SOLUTIONS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"LALLEMAND HEALTH SOLUTIONS \/ MedQualis | Q & T Research","highestDevelopmentStatusID":"8","companyTruncated":"LALLEMAND HEALTH SOLUTIONS \/ MedQualis | Q & T Research"},{"orgOrder":0,"company":"Wake Network, Inc.","sponsor":"Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"PSIL428","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Wake Network, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wake Network, Inc. \/ Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI","highestDevelopmentStatusID":"8","companyTruncated":"Wake Network, Inc. \/ Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"BioLite","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ BioLite","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ BioLite"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"American BriVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"The Lind Partners","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Financing","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ The Lind Partners","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ The Lind Partners"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"University of California","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2022","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ University of California","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ University of California"},{"orgOrder":0,"company":"American BriVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Undisclosed"},{"orgOrder":0,"company":"American BriVision","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2020","type":"Inapplicable","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"American BriVision","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"American BriVision \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"American BriVision \/ Undisclosed"},{"orgOrder":0,"company":"ABVC BioPharma","sponsor":"AiBtl BioPharma","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2023","type":"Licensing Agreement","leadProduct":"Radix Polygalae Extract","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ABVC BioPharma","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.20999999999999999,"dosageForm":"Capsule","sponsorNew":"ABVC BioPharma \/ AiBtl BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"ABVC BioPharma \/ AiBtl BioPharma"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"RBP-6300","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Indivior","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"RBP-8000","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Indivior","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Indivior \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Indivior \/ Undisclosed"},{"orgOrder":0,"company":"Reconnect Labs","sponsor":"University of Zurich","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"RE03","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reconnect Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Reconnect Labs \/ University of Zurich","highestDevelopmentStatusID":"8","companyTruncated":"Reconnect Labs \/ University of Zurich"},{"orgOrder":0,"company":"Motus Therapeutics, Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"RM-131","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Motus Therapeutics, Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Motus Therapeutics, Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Motus Therapeutics, Inc. \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"RO6889450","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"RO6889450","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ropanicant","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ropanicant","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Suven Life Sciences Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ropanicant","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Suven Life Sciences Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Suven Life Sciences Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Suven Life Sciences Limited \/ Undisclosed"},{"orgOrder":0,"company":"Ocuphire Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2011","type":"Inapplicable","leadProduct":"RX-10100","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Ocuphire Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ocuphire Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ocuphire Pharma \/ Undisclosed"},{"orgOrder":0,"company":"S1 Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"S1B-408","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"S1 Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"S1 Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"S1 Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Sen-Jam Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SJP-304","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sen-Jam Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sen-Jam Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sen-Jam Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Synchroneuron Inc.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"SNC-102","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Synchroneuron Inc.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Synchroneuron Inc. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Synchroneuron Inc. \/ Undisclosed"},{"orgOrder":0,"company":"Wei Hao","sponsor":"Beijing Ziduhongye Technology Development | Institute of Pharmacology and Toxicology, Academy of Military Medical Science | Shanghai Mental Health Center | West China Hospital | Wuhan Mental Health Centre","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Thienorphine HCl","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Wei Hao","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wei Hao \/ Beijing Ziduhongye Technology Development | Institute of Pharmacology and Toxicology, Academy of Military Medical Science | Shanghai Mental Health Center | West China Hospital | Wuhan Mental Health Centre","highestDevelopmentStatusID":"8","companyTruncated":"Wei Hao \/ Beijing Ziduhongye Technology Development | Institute of Pharmacology and Toxicology, Academy of Military Medical Science | Shanghai Mental Health Center | West China Hospital | Wuhan Mental Health Centre"},{"orgOrder":0,"company":"PhecdaMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"TJ0113","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"PhecdaMed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"PhecdaMed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"PhecdaMed \/ Undisclosed"},{"orgOrder":0,"company":"Pierre Fabre","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"V0018","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Pierre Fabre","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pierre Fabre \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pierre Fabre \/ Undisclosed"},{"orgOrder":0,"company":"ATAI Life Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"VLS-01-203 BU","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"ATAI Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ATAI Life Sciences \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"ATAI Life Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Acura Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Vycavert","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Acura Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Acura Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Acura Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Warner Chilcott Company, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"WC3036-12F","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Warner Chilcott Company, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Warner Chilcott Company, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Warner Chilcott Company, LLC \/ Undisclosed"},{"orgOrder":0,"company":"22nd Century Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"X-22","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"22nd Century Limited","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"22nd Century Limited \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"22nd Century Limited \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Xiongdan Wan","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"Yuhan Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"YHD1023","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Yuhan Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yuhan Corporation \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Yuhan Corporation \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Shanghai Innovative Research Center of Traditional Chinese Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Yuxintine","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Shanghai Innovative Research Center of Traditional Chinese Medicine","highestDevelopmentStatusID":"8","companyTruncated":"Shanghai Mental Health Center \/ Shanghai Innovative Research Center of Traditional Chinese Medicine"},{"orgOrder":0,"company":"Taisho Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"JAPAN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"TS-121","moa":"Vasopressin receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Taisho Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Taisho Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Taisho Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Balovaptan","moa":"Vasopressin V1a receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"Azevan Pharmaceuticals","sponsor":"Weill Medical College of Cornell University | US Department of Defense | U.S. Army Medical Research and Development Command","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"SRX246","moa":"Vasopressin V1a receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Azevan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Azevan Pharmaceuticals \/ Weill Medical College of Cornell University | US Department of Defense | U.S. Army Medical Research and Development Command","highestDevelopmentStatusID":"8","companyTruncated":"Azevan Pharmaceuticals \/ Weill Medical College of Cornell University | US Department of Defense | U.S. Army Medical Research and Development Command"},{"orgOrder":0,"company":"Azevan Pharmaceuticals","sponsor":"National Institute of Neurological Disorders and Stroke | NeuroNEXT Network","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"SRX246","moa":"Vasopressin V1a receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Azevan Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Azevan Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke | NeuroNEXT Network","highestDevelopmentStatusID":"8","companyTruncated":"Azevan Pharmaceuticals \/ National Institute of Neurological Disorders and Stroke | NeuroNEXT Network"},{"orgOrder":0,"company":"Sanofi","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"Vasopressin V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sanofi \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sanofi \/ Undisclosed"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"Vasopressin V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Undisclosed"},{"orgOrder":0,"company":"HMNC Brain Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Nelivaptan","moa":"Vasopressin V1b receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"HMNC Brain Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HMNC Brain Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"HMNC Brain Health \/ Undisclosed"},{"orgOrder":0,"company":"National Institute on Alcohol Abuse and Alcoholism","sponsor":"AbbVie Inc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ABT-436","moa":"Vasopressin V1b receptor (V1BR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Alcohol Abuse and Alcoholism","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Alcohol Abuse and Alcoholism \/ AbbVie Inc","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Alcohol Abuse and Alcoholism \/ AbbVie Inc"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"ABT-436","moa":"Vasopressin V1b receptor (V1BR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"AbbVie Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"ABT-436","moa":"Vasopressin V1b receptor (V1BR)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"AbbVie Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbbVie Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"AbbVie Inc \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Stanley Medical Research Institute | Columbia University","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Vitamin D receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Stanley Medical Research Institute | Columbia University","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Stanley Medical Research Institute | Columbia University"},{"orgOrder":0,"company":"National Institute on Alcohol Abuse and Alcoholism","sponsor":"Arbor Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Gabapentin Enacarbil","moa":"Voltage-gated calcium channel","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"National Institute on Alcohol Abuse and Alcoholism","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Extended Release","sponsorNew":"National Institute on Alcohol Abuse and Alcoholism \/ Arbor Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"National Institute on Alcohol Abuse and Alcoholism \/ Arbor Pharmaceuticals"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ National Institutes of Health","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institutes of Health"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Levetiracetam","moa":"Voltage-gated N-type calcium channel alpha-1B subunit | Synaptic vesicle glycoprotein 2A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"XEN1101","moa":"Voltage-gated potassium channel Kv7.3 (KCNQ3)","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Xenon Pharmaceuticals Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Undisclosed"},{"orgOrder":0,"company":"Medical Life Care Planners, LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Medical Life Care Planners, LLC","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Medical Life Care Planners, LLC \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Medical Life Care Planners, LLC \/ Undisclosed"},{"orgOrder":0,"company":"Nova Scotia Health Authority","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Nova Scotia Health Authority","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nova Scotia Health Authority \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Nova Scotia Health Authority \/ Undisclosed"},{"orgOrder":0,"company":"Swinburne University of Technology","sponsor":"International Flavors and Fragrances","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Swinburne University of Technology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Swinburne University of Technology \/ International Flavors and Fragrances","highestDevelopmentStatusID":"8","companyTruncated":"Swinburne University of Technology \/ International Flavors and Fragrances"},{"orgOrder":0,"company":"Evon Medics","sponsor":"Howard University | Maryland Treatment Center | Clinics of Dr. Edwin Chapman | National Institute on Drug Abuse","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Evon Medics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evon Medics \/ Howard University | Maryland Treatment Center | Clinics of Dr. Edwin Chapman | National Institute on Drug Abuse","highestDevelopmentStatusID":"8","companyTruncated":"Evon Medics \/ Howard University | Maryland Treatment Center | Clinics of Dr. Edwin Chapman | National Institute on Drug Abuse"},{"orgOrder":0,"company":"Reunion Neuroscience","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Luvesilocin","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Reunion Neuroscience","amount2":0.13,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.13,"dosageForm":"Injection","sponsorNew":"Reunion Neuroscience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Reunion Neuroscience \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Rapport Therapeutics","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"RAP-219","moa":"AMPA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Rapport Therapeutics","amount2":0.25,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.25,"dosageForm":"Tablet","sponsorNew":"Rapport Therapeutics \/ Goldman Sachs & Co","highestDevelopmentStatusID":"8","companyTruncated":"Rapport Therapeutics \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Seaport Therapeutics","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Glyph Allopregnanolone","moa":"GABA receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Seaport Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Seaport Therapeutics \/ Premier Research Group","highestDevelopmentStatusID":"8","companyTruncated":"Seaport Therapeutics \/ Premier Research Group"},{"orgOrder":0,"company":"Beersheva Mental Health Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Beersheva Mental Health Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Beersheva Mental Health Center \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Beersheva Mental Health Center \/ Undisclosed"},{"orgOrder":0,"company":"San Diego Veterans Healthcare System","sponsor":"US Department of Defense | Pop Test Oncology LLC","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"PT150","moa":"Glucocorticoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"San Diego Veterans Healthcare System","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"San Diego Veterans Healthcare System \/ US Department of Defense | Pop Test Oncology LLC","highestDevelopmentStatusID":"8","companyTruncated":"San Diego Veterans Healthcare System \/ US Department of Defense | Pop Test Oncology LLC"},{"orgOrder":0,"company":"Kynexis Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"KYN-5356","moa":"KAT2","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Kynexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kynexis Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Kynexis Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Engrail Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Steroid","year":"2025","type":"Inapplicable","leadProduct":"ENX-102","moa":"GABA A-alpha-2\/3\/5 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Engrail Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Engrail Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Engrail Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"PRT042","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Sichuan Purity Pharmaceutical Technology Co., Ltd.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Spray","sponsorNew":"Sichuan Purity Pharmaceutical Technology Co., Ltd. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Sichuan Purity Pharmaceutical Technology Co., Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Bazelet Nehushtan LtD.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"ISRAEL","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Bazelet Nehushtan LtD.","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bazelet Nehushtan LtD. \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Bazelet Nehushtan LtD. \/ Undisclosed"},{"orgOrder":0,"company":"MapLight Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Public Offering","leadProduct":"ML-007C-MA","moa":"M1\/M4 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"MapLight Therapeutics","amount2":0.26000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0.26000000000000001,"dosageForm":"Tablet","sponsorNew":"MapLight Therapeutics \/ Jefferies","highestDevelopmentStatusID":"8","companyTruncated":"MapLight Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"University Health Network, Toronto","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Controlled Substance","year":"2025","type":"Inapplicable","leadProduct":"Psilocybine","moa":"Serotonin 2a (5-HT2a) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Centre for Addiction and Mental Health \/ University Health Network, Toronto","highestDevelopmentStatusID":"8","companyTruncated":"Centre for Addiction and Mental Health \/ University Health Network, Toronto"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Yasmin Hurd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2015","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Yasmin Hurd","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Yasmin Hurd"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Yasmin Hurd","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jazz Pharmaceuticals \/ Yasmin Hurd","highestDevelopmentStatusID":"8","companyTruncated":"Jazz Pharmaceuticals \/ Yasmin Hurd"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Rebecca Ashare","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"DENMARK","productType":"Peptide, Unconjugated","year":"2018","type":"Inapplicable","leadProduct":"Liraglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Rebecca Ashare","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Rebecca Ashare"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Rebecca Price","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Apimostinel","moa":"Glutamate [NMDA] receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gate Neurosciences \/ Rebecca Price","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ Rebecca Price"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"James Davis","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2018","type":"Inapplicable","leadProduct":"Dextromethorphan","moa":"Glutamate [NMDA] receptor subunit epsilon 1","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Axsome Therapeutics \/ James Davis","highestDevelopmentStatusID":"8","companyTruncated":"Axsome Therapeutics \/ James Davis"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Richard Dart, MD, PhD","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Acetylcysteine","moa":"Glutathione synthetase; Cystine\/glutamate transporter; NAPQI (N-acetyl-p-benzoquinone imine); Aminoacylase-1; Inhibitor of nuclear factor kappa-B kinase subunit beta; Inhibitor of nuclear factor kappa-B kinase subunit alpha; Glutamate receptor ionotropic, NMDA 2B; Glutamate receptor ionotropic, NMDA 1; Glutamate receptor ionotropic, NMDA 2A; Glutamate receptor ionotropic, NMDA 2D; Glutamate receptor ionotropic, NMDA 3A","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Johnson & Johnson \/ Richard Dart, MD, PhD","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson \/ Richard Dart, MD, PhD"},{"orgOrder":0,"company":"FORUM Pharmaceuticals","sponsor":"A. Eden Evins","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"FORUM Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"FORUM Pharmaceuticals \/ A. Eden Evins","highestDevelopmentStatusID":"8","companyTruncated":"FORUM Pharmaceuticals \/ A. Eden Evins"},{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Alexey Mukhin","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWITZERLAND","productType":"Undisclosed","year":"2011","type":"Inapplicable","leadProduct":"NIC002","moa":"Nicotine receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Novartis Pharmaceuticals Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injection","sponsorNew":"Novartis Pharmaceuticals Corporation \/ Alexey Mukhin","highestDevelopmentStatusID":"8","companyTruncated":"Novartis Pharmaceuticals Corporation \/ Alexey Mukhin"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Amsterdam UMC, VUmc","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Corcept Therapeutics \/ Amsterdam UMC, VUmc","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Amsterdam UMC, VUmc"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Christiaan Vinkers","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Mifepristone","moa":"Progesterone receptor | Glucocorticoid receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Corcept Therapeutics \/ Christiaan Vinkers","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Christiaan Vinkers"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Herbert Meltzer","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"JNJ-18038683","moa":"Serotonin 7 (5-HT7) receptor","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Herbert Meltzer","highestDevelopmentStatusID":"8","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Herbert Meltzer"},{"orgOrder":0,"company":"Nimble Science","sponsor":"Valerie Taylor","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Probiotic","year":"2023","type":"Inapplicable","leadProduct":"Fecal Microbiota","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Nimble Science","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Nimble Science \/ Valerie Taylor","highestDevelopmentStatusID":"8","companyTruncated":"Nimble Science \/ Valerie Taylor"},{"orgOrder":0,"company":"Icon Plc","sponsor":"Danisco","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Icon Plc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icon Plc \/ Danisco","highestDevelopmentStatusID":"8","companyTruncated":"Icon Plc \/ Danisco"}]

    Find Psychiatry/Psychology Drugs in Phase II Clinical Development

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emraclidine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Emraclidine Safety, Disease Activity, PK In Adults with Schizophrenia

                            Details : Emraclidine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2025

                            Lead Product(s) : Emraclidine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-932

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Th...

                            Details : ABBV-932 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anxiety Disorders.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            February 26, 2025

                            Lead Product(s) : ABBV-932

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Icalcaprant

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With...

                            Details : Icalcaprant is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 20, 2024

                            Lead Product(s) : Icalcaprant

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emraclidine

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AbbVie’s $9B Bet Collapses as Closely Watched Schizophrenia Drug Fails Studies

                            Details : CVL-231 (emraclidine) is a potential novel M4-selective positive allosteric modulator in development for schizophrenia and other psychosis related diseases.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2024

                            Lead Product(s) : Emraclidine

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABBV-932

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipo...

                            Details : ABBV-932 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bipolar Disorder.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 20, 2024

                            Lead Product(s) : ABBV-932

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Douglas CDMO

                            New Zealand
                            CPhI WW Frankfurt
                            Booth #9.1D6
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEnd-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            R-107 Depression Study Results Published in Nature Medicine

                            Details : R-107 (ketamine) is an oral NMDA receptor negative allosteric modulator, small molecule drug candidate, which is being evaluated for the treatment of treatment-resistant depression.

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            June 25, 2024

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Douglas CDMO

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Darigabat

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder

                            Details : Darigabat is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Panic Disorder.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 12, 2023

                            Lead Product(s) : Darigabat

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Douglas CDMO

                            New Zealand
                            CPhI WW Frankfurt
                            Booth #9.1D6
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothEnd-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Douglas Pharmaceuticals Announces Formation of Clinical Advisory Board for Lead Program R-107

                            Details : R-107, an oral extended-release dose of racemic ketamine being developed as add-on or monotherapy for treatment resistant depression (TRD). It has demonstrated a significant antidepressant effect with maintenance of response at 3 months, high compliance ...

                            Product Name : Undisclosed

                            Product Type : Controlled Substance

                            Upfront Cash : Inapplicable

                            January 26, 2023

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Douglas CDMO

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVL-231

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia

                            Details : CVL-231 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 05, 2022

                            Lead Product(s) : CVL-231

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AbbVie Inc

                            U.S.A
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CVL-231

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia

                            Details : CVL-231 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Schizophrenia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 07, 2022

                            Lead Product(s) : CVL-231

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Abbvie Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth